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Chapter 1 
                     
                  ORIENTATION TO THE STUDY 
 
1.1 INTRODUCTION 
 
Adherence can be described as taking pharmaceuticals according to the medical 
standards after a voluntary agreement has been made between the patient and the health 
care provider. However, adherence beyond this definition also encompasses other health-
related behaviours. “It is the extent to which a person’s behaviour in taking medications, 
following a diet, and/or executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider” (WHO 2003:3). An adherence rate of at 
least 95.0% is necessary to maximise the benefits of antiretroviral therapy (ART). These 
benefits include improved clinical, immunological and virological parameters (WHO 
2006:70). Adherence below 95.0% is associated with a high level of viral drug resistance 
which has public health implications, and poor personal health outcomes (WHO 2003:95). 
Adherence can be measured using different techniques including medication event 
monitoring systems (MEMS), pill counts, biological markers, pharmacy refill data and 
patients’ self-reports (WHO 2003:4-5).  
 
The MEMS cap system utilises a computer chip embedded in a specially designed pill-
bottle cap to record the time and duration of each bottle opening. MEMS adherence 
usually is calculated by dividing the number of time-appropriate bottle openings by the 
number of expected doses over the study period. Pill counts can be conducted in clinics or 
at unannounced home visits. Pill count adherence is usually calculated by counting the 
remaining doses of medication and assuming that the remaining pills are in excess of what 
is expected, representing the missed doses. Biological markers of adherence refer 
primarily to plasma concentrations of antiretroviral drugs (ARVs). Pharmacy refill data can 
serve as an adherence measure by providing the dates on which antiretroviral medications 
were dispensed (WHO 2003). The study considered ≥95.0% adherence level as adherent 
 2 
and <95.0% non-adherent. In Ethiopia there are limited studies available to understand 
adherence determinants and adherence status of patients on ART, required for ART 
programme effectiveness. According to Arnsten, Demas, Farzadegam, Grant, Goureritch, 
Chang, Buon, Echholdt, Howard and Schoenbaun (2001:1423) high levels of adherence 
rates are associated with viral suppression and improved CD4 counts among patients who 
were >95.0% adherent (Wood, Hogg, Yip, Harrigan, O’Shaughnessy & Montaner 
2004:267).   
 
Ethiopia uses first-line and second line ARVs for HIV/AIDS patients who fulfill the ART 
initiation criteria. ART is initiated in Ethiopia based on clinical and immunological 
assessment. Immunological assessment is done using CD4 count; it is best to start ART 
when CD4 count is 200-350cells/ml.  In situations where immunological assessment is not 
possible, ART is initiated based on clinical grounds only. Second line ARVs are reserved 
for those patients who show treatment failure while on first line drugs. Two 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and one non-nucleoside 
reverse transcriptase (NNRTIs) are used as first line drugs while protease inhibitors (PIs) 
are reserved for second line ARVs. Rather than using single ARV doses, Ethiopia uses 
fixed dose combinations (triple or double doses together), which is believed to promote 
patient convenience and adherence to ART (Ethiopian Federal Ministry of health HIV/AIDS 
prevention and control office (EFMOH/HAPCO) 2008:63-82).  
 
There are five interacting dimensions affecting adherence to ART; these include health 
system, patient-related, socioeconomic, therapy-related, and condition-related dimensions 
(WHO 2003:27-30). The independent variables that were analysed in this study are 
patients’ knowledge about HIV and ART, HIV/AIDS stigma and discrimination, depression, 
and alcohol use. 
 
1.2 THE RESEARCH PROBLEM 
 
1.2.1 Source of the research problem 
 
In Ethiopia, since there are few published reports about factors influencing ART 
adherence, little is known about specific strategies to address this issue for HIV positive 
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patients on ART. There are no currently standardised adherence guidelines used 
throughout the country, so each programme and facility develops and follows its own 
unique method for retaining patients on treatment and follow up adherence counseling. 
This has been observed and documented during multiple site visits to hospitals and health 
centers throughout the country. Some health facilities have separate adherence 
counselors while others do not; even health care providers are not quite sure about their 
patients’ levels of ART adherence, and the patient-related factors influencing ART 
adherence. This research topic was selected based on observation from health facilities, 
experiences of ART adherence counselors and the need to fill the gap of research for this 
topic. The factors that were studied are patients’ knowledge about HIV and ART, HIV/AIDS 
stigma and discrimination, depression, and alcohol use and their influence on ART 
adherence 
 
 1.2.2 Background information 
 
In 2007, 33.2 million people globally were estimated to be living with HIV. Two and half 
million people became newly infected and 2.1 million people died of AIDS. In the same 
year  22.5 million people were estimated to be living with HIV, 1.7 million were  
newly infected and 1.6 million had died of AIDS in Sub-Saharan Africa (SSA)  
(UNAIDS/WHO 2007). 
 
HIV prevalence in the overall Ethiopian population is 2.4% but the urban prevalence is 
7.7% while the rural prevalence is 0.9% (EFMOH/HAPCO 2007a). The first evidence of 
HIV/AIDS in Ethiopia was reported in 1984. Ethiopians living with HIV/AIDS number about 
777 500, of whom 242 500 need ART. Of the people in need of ART, 61%  live in urban 
areas, yet urban dwellers constitute an estimated 15.5% of the total population. This 
makes urban areas a potential high yield recruitment area for ART patients to participate in 
research projects (EFMOH/HAPCO Road Map 2007b:09). The adult HIV/AIDS deaths 
accounted for 35.0% of young adults’ deaths. By 2010, there could be 41.0% fewer deaths 
due to the scale-up of ART programmes in the country, provided the ART adherence rates 
remain adequate (EFMOH/HAPCO 2006). Addis Ababa is the capital city of Ethiopia and 
the adult prevalence rate of HIV/AIDS in this area is 9.2% (EFMOH/HAPCO 2007a). This 
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figure is higher than the national prevalence rate, making Addis Ababa a highly affected 
area in the country.  
 
Standard treatment of HIV is the provision of at least three medications to HIV/AIDS 
patients. These medications are known as antiretroviral (ARV) drugs (Ethiopian AIDS 
Resource Center 2009). ART, also known as Highly Active Anti Retroviral Therapy 
(HAART), does not cure but slows down the progression of HIV and improves the health 
outcomes of patients. Once ART is started it should be taken for life with greater than 
95.0% adherence (Ethiopian AIDS Resource Center 2009). Provision of ART is 
challenging in resource limited countries like Ethiopia. However, the country started fee-
based single ARVs initiatives in 2003 and in 2005 providing free ARVs for those HIV 
positive patients eligible to receive ART (EFMOH/HAPCO. 2008: 08). By February 2009, 
there were reportedly 136 344 HIV/AIDS patients on ART (EFMOH/HAPCO 2009) in 
Ethiopia.  
 
In order to obtain the desired health outcomes of ART, adherence plays a key role. 
Adherence refers to voluntary participation of the patient in taking medications according to 
the agreement made with the health care providers. When patients fail to follow the 
instructions about the amount, frequency and duration of ART, the result will be poor 
health outcomes. ART adherence rates of less than 95.0% can result in the development 
of drug resistant mutant viruses which cannot be treated successfully by first line ARVs. 
The first-line ARVs destroy the sensitive viral strains while leaving the resistant ones 
unaffected. These mutants replicate and can be transmitted to the community via sex 
partners, mother-to-child transmission (MTCT), breastfeeding and through shared injection 
needle use which make treatment of HIV/AIDS more challenging. As the number of 
mutants increase, the individual taking ARVs derive fewer benefits from the treatment 
(Ethiopian AIDS resource center 2009).  
 
It has been postulated that there are at least five interacting dimensions affecting ART 
adherence (WHO 2003). These include socioeconomic, patient-related, condition-related, 
therapy-related and health system factors. In developing countries low socioeconomic 
status forces patients to allocate their resources to other competing priorities. There are 
few studies about the health system factors’ influences on adherence. Therapy-related 
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factors are those which are due to medical regimen complexities. Patient-related factors 
influencing adherence to ART, are patients’ knowledge and beliefs about the illness and 
effects of treatment, presence or absence of psychosocial stress, use of alcohol, 
expectation from the treatment and feelings about being stigmatised (WHO 2003). The 
focus of this study is on investigating personal factors’ influences on ART adherence in 
Addis Ababa, Ethiopia.  
 
With the introduction of ART, the previously rapidly fatal HIV/AIDS illness is now becoming 
a chronically manageable illness, which requires taking doses of ARVs every day for the 
rest of the person’s life. A study conducted in Zambia showed that patient-related factors 
facilitating adherence included looking and feeling better, the support of the patients’ family 
and physical reminders and support, in the form of watches or clocks, to take drugs (Grant, 
Logie, Masura, Gorman & Murray 2008:1158). Patient-related factors are personal 
characteristics that determine adherence or non adherence to treatment. These 
characteristics have different variables that can be categorised as alcohol factors, affective 
factors, cognitive factors and social factors (Parsons, Rosof & Mustanski 2007:359). 
Among these factors it has been observed that only alcohol and cognitive factors differed 
for those adherent versus non-adherent to the HIV medication. A significant relationship 
between non-adherence and alcohol abuse has been reported (Chander, Lau & Moore 
2006: 414; Parsons et al. 2007:366; Samet, Cheng, Libman, Nunes, Alperen & Saitz 
2007:198). In a cohort study across 18 primary health care (PHC) centers providing ART in 
Lusaka, Zambia, mortality decreased among those HIV/AIDS patients who adhered to 
ART. It was observed that mortality among HIV patients receiving ART, with less than 
80.0% adherence status, was higher after 12 months than for those patients with more 
than 81.0% adherence (Chi, Cantrell, Zulu, Mulenga, Levy, Tambatamba, Reid, Mwango, 
Mwinga, Bulterys, Saag & Stringer 2009: 751).  Patients with lower adherence levels have 
higher viral load levels making them more likely to transmit the HI virus to their partners in 
comparison to those with lower viral loads (Wutoh, Brown, Kumoji, Daftary, Jones, Barnes 
& Powell 2001:248).  
 
Adherence to ART in Addis Ababa among children is relatively higher in comparison to 
other similar facilities. Reportedly the paediatric ART adherences rates were 93.1% for 
three days and 86.9% for a seven days recall period. This adherence rate was higher 
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among those who used co-trimoxazole prophylaxis (Biadgiligh, Deribew, Amberbir & 
Deribe 2008:8). A study conducted in the southern part of Ethiopia at Yirgalem Hospital 
found that the adherence level was better than that of developed countries. The main 
reasons for non-adherence included being busy or simply forgetting, changes in daily 
routine, and being away from home (Markos, Worku & Davey 2008: 174). A study done in 
the USA found that 29.0% of people taking ART, adhered differentially, implying that they 
had missed one or more of the ARVs while taking the other class of ART medication. 
Adherence in this study was associated with the clinically relevant outcomes of virological 
failure and development of drug resistance (Gardner, Sharma, Peng, Hullsiek, Burman, 
MacArthur, Chesney, Telzak, Friedland & Mannheimer 2008: 77). 
 
ART has become more affordable in developing countries as more people are being 
enrolled in HIV care and treatment. To improve adherence to ART, directly observed 
treatment (DOTS) has been suggested, even though the method has had only limited 
success in the treatment of Tuberculosis (TB) in Africa. Some researchers maintain that 
other methods for improving ART adherence need to be developed and evaluated 
(Stevens, Kaye & Corrah 2004). In Mozambique, it has been learned that recruiting and 
involving specially trained health care providers in public health facilities, who spoke the 
local language, facilitated the involvement of the patients, and motivated them to take 
responsibility for their own treatment. This increased ART patients’ knowledge and 
adherence and improved their health status (Marazzi, Bartolo, Gialloreti, Germano, 
Guidotti, Liotta, San Lio, Mancinelli, Modolo, Narciso, Perno, Scarcella, Tintisona & 
Palombi 2005: 40). 
 
1.3 STATEMENT OF THE PROBLEM 
 
Ethiopia has higher prevalence rates in urban areas versus the rural areas of the country. 
As a result, urban areas have more patients taking ART (EFMOH/HAPCO Road Map 
2007b). By February, 2009, in Addis Ababa alone there were 32 577 patients taking ART, 
out of the total 133 344 national ART clients in Ethiopia (Monthly HIV Care and ART 
Update 2009). This number shows that 24.0% of all ART clients in the country were found 
in Addis Ababa. From this, one could infer that there might be more problems with 
adherence to ART in the capital city. Different variables under patient-related factors were 
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studied to identify their effects on adherence or non-adherence to ART. The factors that 
were studied included patient’s knowledge about HIV and ART, HIV/AIDS stigma and 
discrimination, depression and alcohol use. 
 
 1.4 PURPOSE OF THE STUDY 
 
This study proposed to identify patient-related factors related to ART adherence for HIV 
people living in Addis Ababa. The results would contribute to the body of knowledge of 
adherence in Ethiopia and provide recommendations and directions towards solving 
adherence problems.  
 
 1.5 RESEARCH OBJECTIVES 
 
The objectives of this study were to: 
• Determine the adherence status of ART patients in Addis Ababa, Ethiopia. 
• Identify the influence of patients’ knowledge of HIV and ART on adherence to ART 
in Addis Ababa, Ethiopia. 
• Assess the influence of HIV stigma and discrimination on adherence to ART in 
Addis Ababa, Ethiopia. 
• Evaluate the influence of depression on adherence to ART in Addis Ababa, 
Ethiopia. 
• Identify the influence of alcohol use on adherence to ART  in Addis Ababa, Ethiopia. 
 
1.6 ASSUMPTIONS UNDERLYING THE STUDY 
 
This study assumed that ART patients with adherence level of ≥ 95.0% or more would 
have good health outcomes, improved immunological response and suppressed viral 
loads. Optimal adherence of 95.0% or more, might in turn be influenced by patients’ 
knowledge about HIV and ART, minimal stigma and discrimination, absence of depression 
and low level of alcohol intake.  Structured interviews were conducted with patients while 
they collected their ARVs from the pharmacy.  
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1.7 SIGNIFICANCE OF THE STUDY 
 
The ART programme’s scaling up throughout Ethiopia, resulted in increasing numbers of 
ART patients (EFMOH/HAPCO 2006:35). This study, although specific to Addis Ababa, 
would contribute to the existing knowledge of adherence to ART in Ethiopia. The study will 
inform both programme managers and clinicians about the existing challenges of patient-
related factors influencing adherence to ART and the possible solutions. Policy-makers 
who have the major responsibility for designing and managing the health care programme 
also need to understand these factors. This study could also increase the understanding of 
health professionals in their important role of encouraging maintenance of healthy 
behaviours among their patients. 
 
1.8 DEFINITION OF KEY CONCEPTS  
 
Adherence: The extent to which a person’s behaviour in taking medications, following a 
diet and/or executing lifestyle changes, corresponds with agreed recommendations from a 
healthcare provider (WHO 2003:3). In this study, adherence refers to compliance of the 
patient’s behaviour in taking ARV medication. 
 
AIDS: It defines the acquired immune deficiency syndrome and is used to describe the 
various clinical syndromes, specific opportunistic infections or malignancies that occur with 
HIV infection, and signals those in whom advanced HIV infection has occurred (WHO 
2005:10). AIDS is clinically diagnosed for any person with any one of a specific list of 
diseases (stage 4 conditions), with confirmed HIV infection or immunological diagnosis 
with confirmed HIV infection and first ever documented CD4 count less than 200 per mm3 
(WHO 2007: 9). 
 
Anti-retroviral drugs (ARVs): These are medications which are used in the treatment of 
HIV. The main classes of anti-retroviral drugs are NRTI, NNRTI and PIs. Monotherapy or 
dual therapy with these types of ARVs is not recommended since it is associated with 
virological failure. ART requires the administration of at least three types of ARVs. The 
first-line ARV regimen for adults and adolescents contain two NRTI and one NNRTI. For 
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patients who develop treatment failure, the preferred second-line ARV regimen includes 
two NRTIs and one PI (WHO 2006:17-23). Figure 1.1 indicates the preferred two 
NRTI/NNRTI first-line ARVs and Figure 1.2 shows the possible combination of ARVs that 
make up possible second-line regimens. The ARVs found at the intersection of the 
rectangle and circle, are PIs that constitute the major component of the second-line 
regimen. 
 
 
 
                                                                                                      EFV 
 
                                                                                                     NVP 
 
 
 
Figure 1.1 Preferential two NRTI/NNRTI first-line ARVs (WHO 2006: 19).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 second line ARV regimens (WHO 2006:41) 
 
 
 
Standard second-line option if NRTI/NNRTI 
Approach used in first-line therapy (WHO 2006: 
41) 
 
ddI or TDF 
 
 
 
 
ABC or 3TC (+-AZT) 
                         
PI/r                            EFV or NVP 
                 NRTI sparing option if                                   
triple NRTI approach used in first-line     
therapy (WHO 2006: 41) 
 
AZT or D4T 
                                 3TC or FTC 
TDF or ABC 
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Anti-retroviral therapy (ART): The administration of at least three different ARVs, in order 
to suppress the replication of HIV (WHO 2006:18). Treatment with these combinations of 
drugs is also known as highly active antiretroviral therapy (HAART) (Fauci & Lane 
2005:1124).  
 
Depression: It is having a depressed mood on a daily basis for a minimum duration of two 
weeks. It can be also manifested in the form of loss of interest or pleasure in nearly all 
activities including enjoyable activities (Reus 2005:2553). 
 
Discrimination: Includes both negative attitudes, or particular behaviours or actions 
towards others; often described as a distinction that is made about persons resulting in 
them being treated unfairly and unjustly on the basis of their belonging, or being perceived 
to belong, to a particular group (ENGENDERHEALTH 2004:15). The operational definition 
is unfair treatment of HIV/AIDS patients by their community or health care providers. 
 
HIV: The human immune deficiency virus that damages the body’s immune system, the 
system that fights infections (Longo & Fauci 2005: 1071-1075). HIV is diagnosed among 
adults and children 18 months or older based on positive HIV antibody testing (rapid or 
laboratory-based enzyme immune-assay). This is confirmed by a second HIV antibody test 
(rapid or laboratory-based immune-assay) and/or positive virological test for HIV or its 
components (HIV-RNA or HIV-DNA or ultrasensitive HIV p24 antigen) confirmed by a 
second virological test obtained from a separate determination (WHO 2007: 8).  In Ethiopia 
HIV is diagnosed once the client follows the processes of HIV counseling and testing 
services (HCT). The HCT process encompasses pre-test counseling, testing and post-test 
counseling. Test results are given in post-test counseling. If a person becomes HIV 
positive then he/she is linked to HIV care and treatment services. Results are disclosed to 
the client on the same day of HIV testing (EFMOH/HAPCO 2007c:09).  
 
Stigma: an undesirable or discrediting attribute that a person or group possesses that 
results in the reduction of that person’s or group’s status in the eyes of society 
(ENGENDERHEALTH 2004:15).  The operational definition applicable to this study is a 
person’s or group’s undesirable feelings towards HIV patients. 
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1.9 CONCEPTUAL FRAMEWORK 
 
According to the WHO (2003:27) there are different dimensions affecting adherence to 
ART. These are health system, condition-related factors, therapy-related factors, 
socioeconomic and patient-related factors. The adapted conceptual model for this study is 
the Health Belief Model (HBM).  “The HBM contains several primary concepts that predict 
why people will take actions to prevent, to screen for, or to control illness or conditions. 
These include susceptibility, seriousness, benefits and barriers to a behaviour, cues to 
action, and self efficacy” (Champion & Skinner 2008: 46-47). The authors also defined the 
following concepts which construct the HBM. Perceived susceptibility is a belief about 
the chances of getting a disease or condition. Perceived severity is the belief about how 
serious a disease or a condition or its consequences could be. Perceived benefits refer to 
the beliefs about the advantages of a proposed action. Perceived barriers refer to the 
beliefs about possible disadvantages of the advised action and/or obstacles to be 
overcome to utilise the service/treatment. Cues to action are strategies that activate 
readiness, and self-efficacy is confidence in one’s ability to take action.  
 
The HBM examines how health behaviour changes result after evaluation of the benefits to 
and barriers of action (Munro, Lewin, Swart & Volmink 2007:5). These constructs are 
related to this study, given that if individuals feel that they are susceptible to HIV infection 
then they should perceive the seriousness of the disease and get tested. Once their status 
is confirmed, they should start to think about the benefits available and the associated 
barriers. Perceived barriers include stigma and discrimination. Cues to action in this case 
are information on the availability of ART and the importance of ART adherence. Finally, 
self efficacy is realised when the individual decides to receive ARVs and adhere to the 
treatment. The following diagram is adapted from Champion and Skinner (2008:49) and 
shows these concepts succinctly.   
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Figure 1.3 Concepts of the Health Belief Model (adapted from Champion and Skinner 
2008:49). 
 
1.10 RESEARCH METHODOLOGY  
 
The research methodology provides an entire strategy and defines structures within which 
the study is implemented (Burns & Grove 2005: 211). The research methodology of this 
study is described in detail in chapter 3 of the dissertation. 
 
1.10.1 Research design 
 
The research design followed was cross-sectional, analytical, quantitative, exploratory and 
observational. These design concepts will be addressed in chapter 3 of the dissertation. 
 
Perceived 
susceptibility 
 (I am not at risk of 
HIV; not engaged in 
risky behaviours)  
Perceived severity 
(HIV is a fatal 
disease) 
Perceived benefits 
(The medication will 
make me better) 
Perceived barriers 
(Alcohol use, stigma 
and discrimination) 
Health behaviour 
(I will take and 
adhere to the 
medication)  
Age  
Gender 
Ethnicity 
Personality 
(Depression) 
Socioeconomics 
Knowledge about 
HIV and ART 
Cues to action 
(Information on 
availability of 
ART and the 
importance of 
ART adherence) 
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1.10.2 Research setting 
 
The research was conducted at one hospital in Addis Ababa, Ethiopia. The hospital had  
4 708 patients on ART by the end of February, 2009 (EFMOH/HAPCO 2009). The patients 
on ART during December 2009 who were included in the study provided they had started 
ART at least twelve months previously (during or prior to 1 December 2008). 
 
1.10.3 Population, sample and sampling 
 
The participating hospital, a health facility providing ART services in Addis Ababa, was 
selected because of logistical and financial reasons. By February, 2009 there were 
reportedly 4 708  patients taking ARVs from the participating hospital out of a total of   37 
286 patients taking ART in Addis Ababa (Monthly HIV Care and ART Update 2009). The 
Inclusion criteria for this study were: PLHIV age >=18 years, started ART at least twelve 
months previously, both males and females. The exclusion criteria were those ART 
patients younger than 18 years of age and those who had used ART for less than twelve 
months. According to Burns and Grove (2004:342) the target population is the entire set of 
individuals who meet the sampling (inclusive) criteria. The sampling frame is a list of all 
ART patients taking ARVs at the selected hospital at a specific point in time and who met 
the inclusion criteria. Those patients were chosen using simple random sampling 
techniques. Population and sampling issues will be discussed in chapter 3 of the 
dissertation in more detail. 
 
1.10.4 Data collection instrument 
 
An interview schedule was developed to collect data from patients. Before the interview 
schedule was initially used as a data collection instrument, pre-testing was done. Individual 
questions were well structured in order to avoid ambiguity; interviewers were trained to ask 
questions in a uniform way. 
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1.10.5 Data collection  
 
Structured interviews were used for this data collection. Trained data collectors interviewed 
patients when collected their ARVS from the pharmacy. The questions asked were in line 
with the objectives of the research, allowing calculation of patients’ adherence levels. 
Other information was also collected and included patient’s knowledge about HIV and 
ART, HIV/AIDS stigma and discrimination, depression and alcohol use. 
 
1.10.6 Data analysis 
 
For the statistical analysis procedures the Statistical Package for the Social Sciences 
(SPSS version 17.0) computer software was used.  The services of a statistician were 
employed to do the actual statistical calculations and to assist with the interpretations of 
the statistical results.  
 
1.10.7 Ethical considerations  
 
The research proposal was submitted to the Research and Ethics Committee of the 
Department of Health Studies, Unisa and to the participating hospital’s institutional review 
board clearance (IRB). This was done to confirm that the rights and welfare of the 
individuals involved were protected, the appropriate methods were used to secure 
informed consent and the potential benefits of the investigation were greater than the risks. 
Permission was obtained before data collection started. 
 
1.11 SCOPE AND LIMITATIONS OF THE STUDY 
 
By February 2009, there were reportedly 37 286 ART patients taking ARVs in Addis Ababa 
(Monthly HIV care and ART update 2009). Reaching the representative sample of 37, 286 
ART patients is difficult due to logistical and financial reasons. As a result, the study was 
conducted only at one health facility. The sample taken from only one facility is not 
representative of the whole of Addis Ababa and cannot be used to make inferences to the 
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other health facilities and regions of the country. However, inferences made from the 
sample are applicable to ART patients in the selected health facility. 
 
1.12 ORGANISATION OF THE REPORT 
 
This dissertation has been organised according to five chapters. 
 
Chapter 1 provided an orientation to the study and background information about 
HIV/AIDS in the world, SSA and Ethiopia. It also introduced adherence concepts and the 
research design adopted for the study. 
 
Chapter 2 describes literature reviewed on adherence to ARVs. 
 
Chapter 3 mentions the research design and method used in the study. 
 
Chapter 4 presents the results, analysis and discussions of the findings. 
 
Chapter 5 discusses the conclusions and limitations of this study and provides 
recommendations for minimising patient-related factors influencing adherence to ARTand 
for conducting similar studies in the future. 
 
1.13 CONCLUSION 
 
This chapter presented background information on HIV/AIDS globally, at SSA and at 
country level (Ethiopia) and Addis Ababa city. The following areas were discussed: the 
research problem, purpose of the study, research objectives, assumptions underlying the 
study, significance of the study, definition of key concepts, conceptual framework, research 
methodology, scope and limitation of the study. The study was conducted at one hospital, 
in Addis Ababa. Chapter 2 provides a discussion on literature review of adherence to 
ARVs. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
The literature review will cover reports within the context of HIV/AIDS, ART, adherence to 
ART and patient-related factors influencing adherence to ART. Reviewed documents were 
obtained from websites, journals articles, WHO publications and EMOH publications. The 
literature review covered the period from 2002-2010 
 
2.2 INITIATING ANTIRETROVIRAL THERAPY  
 
The WHO (2007:12) classifies HIV-associated clinical disease as stage 1 (asymptomatic), 
stage 2 (mild symptoms), stage 3 (advanced symptoms) and stage 4 (severe symptoms). 
According to the WHO (2006:13-16), in resource limited countries, ART should be initiated 
based on clinical and immunological assessments. It is important to have clinical staging 
and CD4 count for monitoring patients’ responses to taking ART. Additionally, the process 
of initiating ART involves assessment of patients’ readiness and understanding that ART 
involves life-long therapy, excellent adherence and associated toxicities. ART brings about 
improvements in clinical and immunological outcomes. The optimal time to initiate ART is 
before a patient develops opportunistic infections. Immunological monitoring can be done 
by the use of CD4 counts. When the CD4 count is <200cells/mm3, ART is started 
irrespective of the patient’s clinical stage. When the CD4 count is between 200 cells/mm3 
and 350 cells/mm3 treatment is considered and can be initiated depending on the patient’s 
WHO stage. However, if the CD4 count is above 350 cells/mm3 ART should not be 
initiated. Plasma viral load assessment is not necessary in resource limited countries for 
initiating ART once clinical and CD4 count assessments have been made. 
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The preferred first-line ARV regimen consists of NRTI drugs as the backbone with one of 
the NNRTIs. For treatment-naïve patients TDF and ZDV are preferred first-line NRTIs. 
These drugs can be combined with either 3TC or FTC and given with one of NNRTIs. 
Fixed dose combinations are preferable since they facilitate patient convenience and 
improved adherence. When there is first-line treatment failure a second-line ARV regimen 
is started. Treatment failure can be diagnosed clinically, immunologically and virologically. 
Clinically diagnosed treatment failure occurs when there is clinical progression of HIV 
infection despite documented ART adherence. Immunological diagnosis is made by 
documenting a decline in CD4 counts. Virologic treatment failure occurs when there is a 
rise in viral load. The major component of a second-line ARV regimen is based on PIs 
such as LPV/r or ATV/r. ATV/r with an equivalent efficacy with LPV/r (EFMOH/HAPCO 
2008:50-62).  
 
2.3 ADHERENCE TO ARVS 
 
Key words used in this research were: adherence to anti-retroviral (ARVs), antiretroviral 
drugs, antiretroviral therapy (ART), depression, stigma and discrimination, alcohol use and 
patient’s knowledge about HIV and ART. 
 
2.3.1 Defining adherence 
 
Usually adherence is defined as the extent to which a patient’s taking of his/her medication 
matches the prescribed drug regimen (Ingersoll & Cohen 2008:213). Adherence requires 
informed consent and participation in care and treatment. The patient agrees to follow the 
instructions of the health care provider regarding a drug regimen (Ethiopian AIDS resource 
center 2009). ART patients need to be supported in a variety of ways to adhere to their 
medications: these are client-centered counseling and support; support from peer 
educators and community treatment supporters. These interventions encourage ART 
patients to disclose their HIV status (WHO 2009:42). An adherence rate of ≥95% is 
needed to obtain the benefits of ART; these benefits include better clinical, immunological 
and virological parameters (WHO 2006:70). An adherence level of <95.0% is associated 
with a high level of viral drug resistance, which has public health implications, and poor 
personal health outcomes (WHO 2003:95). 
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In the absence of universally accepted criteria for defining adherence, researchers adopt 
different methods of defining and enumerating appropriate medication-taking behaviour. 
Adherence is commonly measured as a percentage of prescribed medication doses taken 
over a given period of time (Martin, Deborah, Calabresse, Wolters, Rogby, Brennan & 
Wood 2009: 594). Medication adherence can also be described as taking medications 
according to the health care provider’s prescriptions (Cauldbeck, O’Conner, Mortimer, 
Saunders, Rao, Mallesh, Kotehalappa, Kumar, Mamtha, McGoldrick, Laing & Satish 
2009:3). 
 
For this study, adherence refers to compliance of the patient’s behaviour in taking ARVs. 
The adherence level was calculated by dividing self reported ARVs taken by the total 
drugs prescribed over a seven day period. Taking ≥95.0% of the prescribed drug 
(adherence level) was considered as optimal and less than 95.0% suboptimal.  
 
2.3.2 Scope of the problem 
 
Adherence to treatments for chronic diseases in general, tends to be 60% while adherence 
to ART ranges from 55.0% in American patients to 77.0% for African patients (WHO 
2009b:32). Suboptimal adherence has both individual and public health implications. The 
individual implications are poor clinical outcomes and the public health implications are the 
development of drug resistant viral strains.  
 
In another study done in the USA, which assessed ≥95% adherence levels among 244 
HIV patients aged 50-plus, the rate was found to be 80.0% (Johnson, Heckman, Hanson, 
Kochman & Sikkema 2009:541-551). There were also other studies in the USA reporting 
lower adherence levels; one showed  that only 71% of ART patients took their prescribed 
doses and another reported 96.0% of ART patients being adherent less than 95.0% (Golin, 
Liu, Hays, Miller, Beck, Ickovics, Kaplan & Wenger 2002:761). Another USA study showed 
that overall adherence to ART among HIV-infected veterans, starting combination ART, 
was 63.0%: adherence to efavirenz-based ART being 67.0%; nevirapine-based ART 65%; 
and boosted PI 59% (Braithwaite, Kozal, Chang, Roberts, Fultz, Goetz, Gibert, Rodriguez-
Barradas, Mole & Justice 2007:1579-1589). However, according to a study done in 
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Tanzania, a resource poor country, it showed that patients can achieve high levels of 
adherence through persistence adherence counseling in a clinic setting (Mugusi, Mugusi, 
Bakari, Hedgemann, Josiah, Janabi, Aboud, Aris, Swai, Mhalu, Biberfeld, Rollangry & 
Sandstrom 2009:1226-1232). A Zambian study reported that at least 95.0% adherence 
level was documented for 83.7% out of 409 patients for whom pill counts were done 
(Carlucci, Kamanga, Shenberger, Shephered, Jenkins, Spurrier & Vermund 2008:618).  
 
According to the Kip, Ehlers and Van der Wal’s (2009:149-157) study done in Botswana, 
different factors were identified that affected adherence to ARVs both positively and 
negatively.  The negative ART adherence factors were travel expenses, ARVs’ side 
effects, lack of social support, use of traditional medicines, alcohol abuse, and long waiting 
times at ART clinics. The positive ART adherence factors were health workers ensuring 
that ART doses fit into the daily routines of ART patients and explaining to patients how to 
take ART and what  side effects to  expect from ARVs.  
 
ART adherence may also change over time. In a study done in China the mean level of 
adherence was 91.0% at baseline, 89.0% at month three, and 88.0% at month six, 
showing slight decreases over time. The four most common reasons for missing doses or 
discontinuing treatment were forgetfulness (45%), being away from home (44.0%), being 
too busy (33.0%), and having side effects (30.0%) (Wang, Zhou, He, Luo, Li, Yang, Fennie 
& Williams 2009:759). 
 
It has been suggested that ART adherence in Addis Ababa at least among children is 
relatively higher in comparison to other similar facilities in the rest of Ethiopia. Adherence 
levels of 93.1% for three days; recall and 86.9% for seven days recall period were 
documented.  Those who used co-trimoxazole prophylaxis showed a relatively higher level 
of adherence (Biadgilign et al 2008:8). A study conducted in the southern part of Ethiopia 
at Yirgalem Hospital found that the adherence level was better than that of developed 
countries. Being busy or simply forgetting, changes in daily routine, and being away from 
home were the main reasons for non-adherence (Markos et al 2008:174). 
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2.3.3 Role of adherence to ARVs in HIV/AIDS 
 
According to the WHO (2006:9) “ART should be delivered as part of a package of care 
interventions, including the provision of co-trimoxazole prophylaxis, the management of 
opportunistic infections and co-morbidities, nutritional support and palliative care”. Ethiopia 
started fee-based ART initiatives in 2003 and free ART in 2005 (EFMOH/HAPCO. 
2008:08). The first free ARV service in Ethiopia began at hospitals in March, 2005. The 
government of Ethiopia then started accelerated access to ART in 2006 which had 
reached 260 ART sites against a target of 89 (EFMOH/HAPCO Road Map 2007a: 10). By 
February 2009, there were reportedly 136 344 HIV/AIDS patients on ART in Ethiopia 
(EFMOH/HAPCO 2009).  
 
There are challenges in the scaling up of access to ART nationally.  The main challenge is 
patient attrition from ART treatment. The three underlying causes are treatment stoppage, 
death and being lost to follow-up actions. Treatment stoppage refers to permanent or 
temporary interruption of ART as decided by the health care provider with the patient such 
as in cases of drug toxicities. Death is calculated from the number of patients alive after a 
period compared to the total number of people who started treatment; in many low and 
middle income countries the information is not easily available. An ART patient is 
considered lost to follow-up when he or she fails to return for refills of their ARVs. These 
challenges highlight that ART requires close follow-up actions and monitoring since the 
treatment needs life-long adherence to ARV medications (WHO 2009c:61).   
 
Adherence to ART is recognised as the key to both programmatic and individual level 
treatment success. Adherence is helpful for delaying or avoiding resistance to first-line 
ARVs. For this, adherence counseling of patients helps them to understand how to take 
the medications, and what to do in case of developing ARVs’ side effects. For adherence 
counseling, family or community members should be engaged to build patient support, and 
to avoid stigma and discrimination (WHO 2006:70-71)  
 
Suboptimal adherence is the most common cause of developing viral resistance. Accurate 
and reliable measures of adherence are needed for transition from reactive prevention to 
proactive prevention of viral resistance in the management of HIV. There are promising 
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approaches to improving adherence monitoring including interviewing patients about 
recent missed doses, reviewing pharmacy-dispensing information and using medication 
containers with electronic monitoring (MEMS). Even though adherence may decline 
overtime the best approach of predicting future adherence is past adherence (Bangsberg 
2008:272). 
 
2.3.4 The relationship between adherence and treatment outcomes 
 
According to a study done in Lusaka, Zambia by Chi, Cantrell, Zulu, Mulenga, Levy, 
Tambatamba, Reid, Mwanga, Mwinga, Bulterys, Sage and Stringer (2009:748) high levels 
of adherence to ART are associated with favourable patient outcomes. The authors 
conducted a cohort study among 27 115 treatment-naïve patients who initiated and 
continued ART for ≥12months: 17 060 (62.9%) demonstrated optimal adherence, 7682 
(28.3%) had suboptimal adherence and 2373 (8.8%) had poor adherence. Mortality risk 
was similar for those who optimally and sub optimally adhered to ART but higher among 
those with poor adherence.  CD4 increases were relatively good for those optimally and 
sub optimally adherent but appeared to be worse for those who adhered poorly. 
 
Adherence to ART reduces viral replication and prevents the emergence of drug resistant 
strains of HIV. Different studies have shown that high levels of adherence in Africa are 
possible despite resource limitations. An additional study conducted in Lusaka, Zambia 
revealed that decreased adherence levels (measured by medication possession ratio) 
among ART patients is associated with detectable HIV viremia (Goldman, Cantrell, 
Mulenga, Tambatamba, Reid, Levy, Limbada, Taylor, Saag, Vermund, Stringer & Chi 
2008:1032). Braithwaite et al (2007:1579-1589) reported similar findings: a higher level of 
adherence to ART was associated with viral suppression and increased CD4 cell counts. 
  
A study conducted in South Africa suggested that the type of health service delivery site is 
associated with suppression of virological measures in addition to good adherence. The 
factors which may influence virological outcome negatively at a health facility include  long 
waiting times for clients; using staff members without specialised training in HIV care; 
failure to contact individuals who do not attend clinic and lack of communication between 
pharmacy and clinic staff members (Fielding, Charalambous, Stenson, Pemba, Martin, 
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Wood, Churchyard & Grant 2008:4-7). Compared with HIV positive adults in Southern 
Africa, adolescents are less adherent and have lower rates of viral suppression, 
immunological recovery and a higher rate of viral rebound (Nachega, Hislop, Nguyen, 
Dowdy, Chaisson, Regensberg, Cotton & Maartens 2009:69). 
 
Virologic failure was associated with low CD4 cell count, low past adherence, shorter 
duration of prior suppression and intravenous drug use. A study in the USA showed that 
while high levels of adherence are required for viral suppression in the long term, the 
range of adherence capable of sustaining viral suppression is wider after extended periods 
of viral suppression (Rosenblum, Deeks, van der Laam & Bangsberg 2009:6).  
 
2.3.5 Factors affecting adherence to ARVs 
 
According to the WHO (2003:27-35) there are five interacting factors that influence 
adherence to medication. The five factors are socioeconomic factors, therapy-related 
factors, patient-related factors, condition-related factors and health care and system-
related factors. Patient-related factors include forgetfulness, schedule, attitude and 
knowledge about HIV treatment, and whether patients need to take medication in secret. 
Patient-related factors are just one dimension and not the sole factor responsible for 
influencing adherence to medication. When designing programmes that address 
adherence to medication, it is important to take into consideration all other factors. 
Socioeconomic factors are related to food security, employment and degree of social 
support. Therapy-related factors are complexities of drug regimens, side-effects, toxicities 
and their management. Condition-related factors are associated with the stage of the 
disease, severity of symptoms and occurrence of co-morbidities. Health care and system-
related factors are health care reimbursement systems and the cost of medications and 
consultations, drug distribution systems and the availability of medicines, access to health 
services, levels of confidentiality in the health care setting and the conditions of the 
medical encounter. 
 
Other patient-related factors affecting adherence include the patients’ mental health status, 
income levels and gender. A multivariate analysis study conducted in Stockholm, Sweden, 
found that anxiety interfered with adherence dose instructions. The study further 
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mentioned that suboptimal adherence might be a symptom of psychological distress or a 
coping strategy of adjusting ART to one’s daily living in addition to a behavioural pattern 
(Schonnesson, Williams, Ross, Bratt & Keel 2007:181-183). A study at the Yaonde central 
hospital in Cameroon found out that 70% of patients who had started ART six months prior 
to the data collection, were still returning to the hospital for pharmacy refills, 17% 
disappeared, 9% died and 4% were referred to other health facilities. As compared to the 
poorest and richest ART patients, people with middle income were more adherent while 
female gender and having fewer side effects from ARVs were associated with higher rates 
of pharmacy adherence (Rougemont, Stoll, Elia & Ngang 2009:7-9).  
 
Stigma has been associated with suboptimal adherence both in resource poor and rich 
countries and this relationship is partially mediated by lower mental status (Sayles, Wong, 
Kinsler, Martins & Cunningham 2009:1105-1108). A cross sectional and descriptive study 
done in South East Nigeria reported different factors associated with non-adherence: 75% 
of the respondents were not fully adherent to ART. In addition to previously mentioned 
factors of non-adherence including ART side effects, non-availability of drugs at treatment 
site, forgetting to carry drugs during the day, other  associated factors included  fear of 
social rejection, treatment being a reminder of HIV status, and selling of own drugs to 
those unable to enroll in the projects. Additionally being female, over 35 years old and high 
education status were significantly associated with non-adherence (Uzochukwu, 
Onmujekwe, Onoka, Okoli, Uguru & Chukwuogo 2009:192).   
 
According to Golin et al (2002:759), a US-based multivariate analysis study,  being of 
African-American ethnicity, having lower income and education, alcohol abuse,  having a 
higher medication dose frequency and fewer adherence aids (such as pillboxes, timers) 
were independently associated with poor adherence. On the other hand, Carlucci et al 
2008:620 in a study done in rural Zambia found that travel-related factors did not predict 
adherence. Patients in rural Zambia achieved adherence rates well-matched with good 
clinical outcomes despite long travel distances. A study conducted in southwest Ethiopia at 
the ART unit of Jimma University specialist hospital, showed that depression was 
associated with non-adherence. Adherence was common among those who had social 
support systems. More than 75% of the respondents reported that they missed doses due 
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to forgetting, feeling sick or ill, being busy, and running out of medications (Amberbir, 
Woldemichael, Getachew, Girma & Deribe 2008:6-7).    
 
The literature review has shown that adherence to ART can be affected by various factors. 
This study focused on personal factors influencing adherence to ART. The variables that 
were analysed in this study are patients’ knowledge about HIV and ART, HIV/AIDS stigma 
and discrimination, depression, and alcohol use. 
 
2.3.5.1 Stigma and discrimination 
 
A study conducted on Zambian women revealed stigma to be one of the major barriers to 
adherence to ART. Even though ART is to be taken life-long once started, significant social 
stigma may partially or completely disrupt patients’ drug adherence levels. The studied 
women described stigma in different ways: shyness, fear of being laughed at, fear of being 
embarrassed or that others would know their status, fear of being seen as a prostitute. 
Finally the study discussed ways for addressing stigma to bring about successful ART 
adherence (Murray, Semrau, McCurely, Thea, Scott, Mwiya, Kankasa, Bass & Bolton 
2009:82). In another study done in the USA, the association between stigma and ART 
adherence was reported to be mediated by the patients’ mental health status.  
 
Poor mental health status coupled with stigma, resulted in suboptimal adherence to ART. 
Self-reports of poor medical care were associated with experiencing stigma. PLHIV 
diagnosed within the last five years experienced greater levels of stigma as compared to 
those who had been diagnosed for more than five years. This suggests that stigma might 
reduce over time (Sayles et al 2009:1104-1105). A study done in five African countries 
(Lesotho, Malawi, South Africa, Swaziland and Tanzania) found that stigma interfered with 
adherence to ART. Percieved stigma was correlated with missed ART doses. Accordingly 
the study suggested that health care providers should be expected to discuss stigma-
related issues with their patients before the commencing ART (Dlamini, Wantland, 
Makoae, Chirwa, Kohi, Greeft, Naidoo, Mullan, Uys & Holzemer 2009:384).  
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2.3.5.2 Knowledge about HIV and ART 
 
A Zambian study conducted among urban women, found that lack of information regarding 
HIV and ART was associated with non-adherence to ART. In the absence of adequate 
information about HIV and ART, when patients felt better, they discontinued ART, thinking 
that their HIV had been cured.  Not enough patient information was given when health 
workers were overburdened and had limited time with each patient (Murray et al 2009:84). 
The South African study in Soweto found that knowledge scores among HIV positive 
people attending clinical care, was 86%.  Their knowledge was evaluated in terms of 
cause, mode of transmission and progression of HIV. The knowledge gained through 
media and during counseling sessions at health facilities was well understood by HIV 
patients. Among patients taking ART, a high level of knowledge regarding ART and its  
importance in controlling the infection was observed (Nachega, Lehman, Hlatswayo, 
Mothopeng, Chaisson & Karstaedt 2005:196-201). Another study done in Rio de Janeiro, 
Brazil, reported that HIV patients who had been taught by health care providers how to 
take ARVs, had better adherence levels. This study suggested that interventions that help 
to improve patient-health care provider interactions were necessary for better adherence to 
ART (Filho, Nogueira, Machado, Abreu, De Oliveira, Evangelista & Hofer 2008:687).  
 
2.3.5.3 Alcohol use 
 
According to Ruthlind, Greenfield, Bruce, Meyerhoff, Flenniken, Lindgren & Weiner 
(2005:80) a study done in the USA, heavy drinking among HIV-infected individuals was 
associated with adverse effects on neuropsychological functioning and reduced self-
reports of adherence to ART. The observed neuropsychological effects included deficits in 
processing and auditory working memory, balance and executive functions. A USA based 
study showed that moderate and hazardous alcohol use was associated with poor 
adherence to ART.  This relationship was further aggravated by concurrent use of drugs 
and alcohol (Chander et al 2006:415). Another study in the USA found differences in levels 
of adherence among those who used alcohol and those who did not do so. The amount of 
drinking affected adherence to ART; frequent and heavy alcohol drinkers were less ART 
adherent than infrequent and light alcohol drinkers (Parsons et al 2007:366). 
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2.3.5.4 Depression 
 
In a multiple logistic regression analysis study done in Ethiopia, PLHIV who were not 
depressed, adhered two times more than those who were depressed. Social support was 
also positively associated with adherence to ART (Amberbir et al 2008:5). A South African 
study, conducted among black women, also revealed the same result that suboptimal 
adherence was associated with depression (Aspeling & van Wyk 2008:7). A prospective, 
observational cohort study among past or current alcohol problems in Spain, found that 
patients with depressive symptoms were twice more likely to discontinue ARVs after six 
months of follow-up treatments. Therefore the management of depressive symptoms 
among HIV patients with alcohol problems is important to improve adherence to ART (Kim, 
Palepu, Cheng, Libman, Saitz & Samet 2007:1042-1044). A quantitative cross-sectional 
study done in India also showed similar findings, that depression was associated with poor 
adherence. Health care providers were advised to identify the presence of depression and 
manage it accordingly as early as possible in order to improve adherence to ART (Sarna, 
Pujari, Sengar, Garg, Gupta & Van Dam 2008:34-35). 
 
2.3.5.5  Gender differences  
 
In a study done in the US, women initiating ART, spent more time off therapy than men, 
and women were more likely to discontinue or change ARV regimens due to neurologic, 
dermatologic or symptoms such as rash, peripheral neuropathy, fatigue, weight loss, and 
feelings of vertigo/dizziness. The number of people off therapy was higher in black women 
than white women, white men and black men. The study further suggested that adherence 
strategies and interventions needed to target African American women (Kempf, Pisu, 
Dumcheva, Westfall, Kilby & Saag 2009:339-340). Another study done in Nigeria also 
showed that being female, single and having a higher educational status were significantly 
associated with non-adherence to ART (Uzochukwu et al 2009:192) 
 
2.3.5.6 ARVs’ side effects 
 
According to Canestri, Sow, Vray, Ngom, M’boup, Kane, Delaporte, Gueye, Peytavin, 
Girard & Landman (2007:5-6) in a study conducted in Senegal, different side effects from 
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ARV could occur affecting adherence levels. These include EFV-related central nervous 
system symptoms (mainly dizziness), peripheral nuerophathy and severe neuropathies 
with incapacitating and intolerable discomforts. A different study by De Padua, Cesar, 
Bonolo, Acurcio & Guimaraes (2007:23) in Brazil showed that 92.2% of the studied sample 
had at least one and 52.6% had four or more different types of adverse reactions in the 
initial period of ART. The most frequently reported adverse reactions were gastrointestinal 
effects. There were increased frequencies of reported regimen switches as a result of 
having adverse reactions. The patients’ perceptions of having adverse reactions could 
contribute to non-adherence and discontinuation of ART. According to Uzochukwu et al 
(2009:192) side effects of ARVs and unavailability of drugs from the treatment site were 
associated with non-adherence to ART in Nigeria. According to Johnson and Neilands 
(2007:583) a study done in the USA found that patients on ART intentionally skipped their 
medications in order to avoid side effects from the treatment. Skipping of medication has 
been observed among those with limited understanding of how ART works, those who had 
poor interactions with their health care providers, those with limited disclosure of their HIV 
status to their family members and friends and those with greater intrusiveness of HIV 
treatment on their lives. 
 
2.3.5.7 Socioeconomic status 
 
A study done in the USA compared ethnicity and risks of AIDS and death among HIV 
infected patients with access to care. Among the studied ethnic groups, lower adherence 
rates were observed for Hispanic and Blacks as compared to  Whites. There was also a 
surprising result that better survival was observed among Hispanics despite poor 
adherence to ART, reduced immunological responses and lowered census-based socio-
economic status as compared to Whites. This might be explained based on differences in 
diet, genetics and extended family support (Silverberg, Leyden, Quesenberry & Horberg 
2009:2070).  
 
A different USA study examined the role of neighborhood socioeconomic context on 
racial/ethnic differences in AIDS treatment and survival in San Francisco. The relative risk 
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of mortality from AIDS was higher among residents of the lower neighborhood 
socioeconomic context. However, this effect was reduced after ART initiation. Blacks 
demonstrated greater delays in obtaining or having no treatment relative to other groups 
(Arnold, Hsu, Pipkin, McFarland & Rutherford 2009:8-9). 
 
2.3.6 Measuring adherence  
 
Adherence can be measured using different techniques including MEMS, pill counts, 
biological markers, pharmacy refill data and patient self-reports (WHO 2003:4-5). The 
MEMS cap system utilises a computer chip embedded in a specially designed pill-bottle 
cap to record the time and duration of each bottle opening. MEMS adherence usually is 
calculated by dividing the number of time-appropriate bottle openings by the number of 
expected doses over the study period. Pill counts can be conducted in clinic or at 
unannounced home visits. Pill count adherence is usually calculated by counting the 
remaining doses of medication and assuming that the remaining pills are in excess of what 
is expected and represent the missed doses. Biological markers of adherence refer 
primarily to blood or urine concentrations of non-toxic biological markers. Pharmacy refill 
data can serve as an adherence measure by providing the dates on which antiretroviral 
medications were dispensed. Patient-self-report measurements are done by asking 
patients for their subjective rating of their adherence behaviours (WHO 2003:4).  
 
2.3.6.1 Medication event monitoring system (MEMS) 
 
The South African study on pediatric patients compared the adherence rate measured by 
MEMS and care giver self-report with virologic suppression. For 73 children followed, the 
median adherence measured by MEMS was 87.5% and the median caregiver self-report 
adherence was 100%. Overall 65% of children achieved virologic suppression and MEMS 
adherence was significantly associated with virologic suppression (Muller, Bode, Myer, 
Roux & Von Steinbucher 2008:257). Another study done in Botswana, supports the finding 
that MEMS is a more reliable measure of adherence level as compared to self-report. It 
can be used to measure adherence levels in low resource-limited countries (Vriesendrop, 
Cohen, Kristanto, Vrijens, Rakesh, Anand, Iwebor & Stiekema 2007:1119). MEMS has an 
advantage of being sensitive in detecting non-adherence and useful for pharmacokinetic 
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studies. However, MEMS is costly, relies on the assumption that pills are taken when, and 
only when the pill cap is removed and is feasible only in specific contexts (WHO 
2009b:37). 
 
2.3.6.2 Pill counts 
 
According to Paterson, Potoski and Capitano (2002:103-206), pill counts are usually 
performed at clinic when patients bring their bottles with them. A health care provider 
counts the number of pills remaining in the bottle and computes the number of missed 
doses by comparing the difference between the actual and expected number of pills 
remaining in the bottle. The disadvantage of pill count is that patients may dispose pills 
before coming to the clinic hoping to appear as being ART adherent. An unannounced pill 
count may solve this problem. A US-based study investigated the use of announced pill 
counts to calculate the adherence status; the study found that there is a high correlation 
between an announced pill count and a visual analogue scale of adherence administered 
to patients. This suggests that both measurements of adherence provide similar findings 
for the same patients (Giordano, Guzman, Clark, Charlebois & Bangsberg 2004:76).  
 
Phone call pill counts provide the same adherence levels as home-based pill counts. 
Phone call pill counts could save time and money needed to undertake home-based pill 
count. This requires that ART patients do not give wrong numbers of missed doses while 
the evaluator conducts the phone call pill counts. However, the time does not allow the 
patient to calculate the expected numbers of missed doses from the previous call to the 
current call while the assessor is on the phone (Kalichman, Amaral, Stearns, White, 
Flanagan, Pope, Cherry, Cain, Eaton & Kalichman 2007:1006).  
 
2.3.6.3 Biological markers  
 
Non-toxic biological markers can be added to the patients’ medications and their detected 
presence in the blood or urine could provide evidence that the required doses had been 
taken. The drawback of this is that these measurements might be misleading and 
influenced by a variety of individual factors such as diet, absorption and rate of excretion 
(WHO 2003:5).  
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2.3.6.4 Pharmacy refill data  
 
Pharmacy databases can be used to check the time of prescription being initially filled, 
refilled over time, or if prematurely discontinued. From these dates and prescribed 
dosages, adherence levels can be measured. The problem associated with pharmacy refill 
data is that picking up the drug does not ensure its ingestion (this would overestimate 
adherence if not accounted for).  Pharmacy information might be incomplete, since 
patients might use more than one pharmacy and this data might not be captured, and if 
captured, it might not be available to different pharmacies (WHO 2003:5). Adherence 
measures, using pharmacy refill data, can be conducted easily but relies on accurate and 
complete record keeping (WHO 2009b:37).  According to a study conducted among nine 
Southern African countries, adherence measurements using pharmacy refill data, were as 
accurate as CD4 count changes for detecting virologic failure. This finding suggested that 
pharmacy refill data adherence measurements could be considered as alternatives to CD4 
counts for the monitoring of patients with high probabilities of virologic failures (Bisson, 
Gross, Bellamy, Chittams, Hislop, Regensberg, Frank, Maartens & Nachega 2008:785). 
 
2.3.6.5 Self-reports 
 
Patients’ self-reports are practical measures of adherence and using 3-4 day recalls of pills 
taken divided by the total number of pills prescribed for that period, had been used to 
calculate adherence estimates (Jerant, Dimatteo, Arnsten, Moore-Hill & Franks 
2008:1134). According to a US-conducted adherence study, patients usually tell their 
physicians why they are taking ART. However, half of the participants who were not 
adherent to ART did not tell their physicians the reasons for missed doses, because they 
anticipated that the physician would not support their decisions, lacked trust in the 
physicians’ opinions and were unable to discuss their feelings or spiritual or moral issues 
(Kremer & Ironson 2006:526). Another study done in Italy used self-report for measuring 
adherence to ART on patients taking PI based ARVs and found that missed doses of 
drugs were associated with low plasma drug levels. This suggests that patient self-reports 
might be a valid method for identifying non-adherence (Murri, Ammassari, Gallicano, De 
Luca, Cingolani, Jacobson, Wu & Antinori 2000:123-128). 
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A study done in the USA showed that self-reports of <95.0% adherence levels were 
associated with higher concentrations of HIV RNA. This suggested the usefullness of self-
reports for measuring adherence (Sullivan, Campsmith, Nakamura, Begley, Schulden & 
Nakashima 2007:3). A different USA study found out that self-reports on adherence to 
ART using 3-day recalls and 7-day recalls had similar virologic and immunologic 
outcomes. The adherence levels measured by these two recall periods were the same 
(Mannheimer, Thackeray, Hullsiek, Chesney, Gardner, Wu, Telzak, Lawrence, Baxter & 
Fiedland 2008:165). 
 
2.4 SUMMARY 
 
Adherence levels of ≥95.0% are required for optimal clinical and immunological ART 
outcomes. If patients fail to have at least 95.0% adherence to ART the result can be a poor 
clinical outcomes, immunological responses and treatment failures. Poor adherence can 
also result in the development of viral resistant strains which can be transmitted among 
members of the community through unsafe sexual practices, mother-to-child transmission 
or blood transfusions. Generally, adherence to ART is higher than adherence to treatment 
for other chronic illnesses. Studies on ART adherence in developing countries dispelled 
previous conceptions that high adherence levels in resource poor countries were 
unachievable. 
 
Different factors affect adherence to ART and can be classified as socioeconomic therapy-
related, patient-related conditions and health care and system-related factors. Patient-
related factors are the focus of this study. Adherence can be measured by MEMS, pill-
counts, biological markers, pharmacy refill data and patient self-reports. This study used 
patient-self-report as a measure of adherence to ART. 
 
Chapter 3 will discuss the research methodology to identify the relationship between 
patients’ knowledge about HIV and ART, HIV/AIDS stigma and discrimination, depression, 
and alcohol use and adherence to ART. 
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CHAPTER 3 
RESEARCH DESIGN AND METHOD 
 
3.1 INTRODUCTION 
 
The data were collected by a health worker trained by the researcher. The data collection 
instrument was a structured interview schedule which had been designed by the esearcher 
and used to collect information about only the variables of interest. Quantitative research 
methodology was followed. 
 
3.2 STUDY DESIGN 
 
A quantitative, descriptive, cross-sectional and analytical study was conducted. Applied 
research is one type of quantitative research that contributes to the improvement of clinical 
or public health practice. Its purpose is to solve problems that exist in real life practice 
situations like public health or medical practice (Burns & Grove 2005:33). This study 
investigated the determinants of Anti-Retroviral Therapy (ART) adherence and involved 
addressing some of the challenges affecting patients when using the public health 
approach to delivering ART and proposed possible solutions for addressing these 
challenges. The study could be considered to be applied research contributing to 
identifying and addressing patient-related factors affecting ART adherence in Ethiopia.  
 
3.2.1 Cross-sectional 
 
A cross-sectional design is used to examine groups of subjects in various stages of 
development simultaneously with the intent to describe changes in the phenomenon 
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across stages (Burns & Grove 2005:236). People living with HIV (PLHIV), who started ART 
at different times were studied simultaneously in this case. The two groups of people 
identified in the study were those who adhered to ART and those who did not adhere to 
ART. Adherence rates of more than or equal to 95.0% were considered as adherent, while 
adherence rates of less than 95.0% were considered to be non-adherent. In this study the 
association between patient-related factors, adherence status and adherence behaviour 
were examined.  
 
In a cross-sectional study, the researcher usually selects the sample without reference to 
exposure; often the sample is drawn at random from a defined population (Morroni & Myer 
2007:85). The chosen exposure variables were patients’ knowledge about HIV and ART, 
HIV/AIDS stigma and discrimination, depression, and alcohol use. These variables were 
not considered during the selection of respondents.  
 
The cross sectional analytical design allowed evaluation of the relationship between 
exposures and outcomes and it was useful for assessing the health care needs of 
populations. The disadvantage of the cross-sectional design is, compared to cohort and 
case control studies, that it provides weaker evidence about the causation of disease 
(Morroni & Myer 2007:87).  
 
3.2.2 Quantitative 
 
Burns and Grove (2005: 23) described quantitative research as “a formal, objective, 
systematic process in which numerical data are used to obtain information about the 
world”.  Quantitative research helps to understand variables and examine relationships 
between dependant and independant variables. Statistical tests were used to examine the 
relationship between variables. Creswell (2003:18) defined the quantitative approach as 
where “the investigator primarily uses postpositivist claims for developing knowledge (such 
as cause and effect thinking, reduction to specific variables and hypotheses and questions, 
the use of measurements and observations, and the testing of theories), employs 
strategies of inquiry such as experiments and surveys, and collects data on predetermined 
instruments that yield statistical data”. Applied research is one type of quantitative 
research that contributes to the improvement of clinical or public health practice. Its 
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purpose is to solve problems that exist in real life practice situations like public health or 
medical practice (Burns & Grove 2005: 33). This study was an investigation of the patients’ 
determinants of ART adherence. Hence, it involves dealing with some of the challenges 
affecting the public health approach to delivering ART and proposing possible solutions. 
The study could be considered to be applied research that contributes to identifying and 
addressing patient-related factors affecting adherence to ART. 
 
3.2.3 Descriptive  
 
This study, intending to identify the patients’ ART adherence levels, was best approached 
using a descriptive study. Descriptive studies are used to measure the extent of a health 
problem or the burden of disease in a population. It describes the occurrence of disease in 
a population such as prevalence or incidence (Morroni & Myer 2007:78).  
 
3.2.4 Analytical 
 
An analytical study design is used to find the factors that predict or cause health problems. 
In the case of a cross sectional study, an analytical design can be used in combination 
with a descriptive study. While a descriptive study describes the outcome of interest, an 
analytical design examines the relationship between an exposure and an outcome 
(Morroni & Myer 2007:78-79). In this study the outcome is ART adherence level while the 
exposures are patients’ knowledge about HIV and ART, HIV/AIDS stigma and 
discrimination, depression, and alcohol use.  
 
3.3 RESEARCH METHOD 
 
This Section covers the steps involved in the data collection and sampling. It also provides 
information about the research setting and population. 
 
3.3.1 Research setting 
 
The research was conducted at one hospital in Addis Ababa, Ethiopia, because it provided 
treatment to a large number of ART patients during the study period. There were 
reportedly 4 708 patients on ART by the end of February, 2009 at this hospital 
(EMOH/HAPCO 2009). The patients receiving ART came from different backgrounds, 
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used ART for different periods of time, had different adherence levels, ages, education 
status and included both males and females.  
 
3.3.2 The research population 
 
According to Burns and Grove (2005:342) the target population is defined as the entire set 
of individuals who meet the sampling (inclusion) criteria. The participating hospital, a 
health facility providing ART services in Addis Ababa, was conveniently selected for 
logistical and financial reasons. By February, 2009 there were reportedly 4 708 ART 
patients at this hospital from the total 37 286 patients taking ART in Addis Ababa 
(EFMOH/HAPCO 2009).  These patients comprised the accessible population, which is the 
subset of target population that the researcher can access (Burns & Grove 2005: 342).The 
inclusion criteria for this study were: PLHIV age ≥18 years and started ART at least twelve 
months previously. The exclusion criteria were those ART patients younger than 18 years 
of age and those who had used ART for less than twelve months.  
 
3.3.3 The sampling process and the sample 
 
The sampling frame is a list of all ART patients at the selected hospital at a specific point in 
time who met the inclusion criteria. Those patients were chosen using simple random 
sampling techniques. In simple random sampling, each individual is chosen by chance and 
subjects have a known chance of being included in the sample (Joubert & 
Katzenellenbogen 2007:96). Potential respondents were identified using their ART unique 
numbers. These numbers were obtained from the ART clinic and randomly chosen using a 
table of random numbers until the desired sample size had been reached. The selected 
ART numbers were cross checked with patients’ identifications and each chosen patient 
was contacted when he or she came to the hospital for ART refills. The data were 
gathered from these patients following their voluntary agreement to participate and their 
signing of the informed consent forms.  
 
The formula used for the sample size calculation was S=p(1-p)z2 /d2 where p stands for 
anticipated population proportion, z refers to the cut-off value of the normal distribution and 
d is the precision required on either side of the proportion (Sayed 2007:347). The 
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assumptions for sample size calculations were 95.0% confidence interval, 50.0% 
frequency of adherence and 5.0% worst acceptable result. Hence S became 384 but when 
the adjusted sample size was calculated, using S/ (1+S/Pop), it resulted in 355 patients 
comprising the sample. Where Pop is the known number of a population (The survey 
system 2007), the adjusted sample size was used considering the size of the target 
population of 4 798. 
 
3.4 DATA COLLECTION 
 
The data were collected from ART patients by conducting structured interviews; and using 
an interview schedule prepared for this purpose. Two data collectors were recruited and 
trained by the researcher. The data collectors were health professionals with prior 
knowledge of adherence to ART. They received training in data collection for two days; the 
training including both theoretical instruction and practical exercises. The exercises were 
conducted using the structured interview schedule with each other. The theoretical part of 
the training covered different topics relevant to this study’s and data collection procedures. 
Specific topics included ART, adherence to ART, factors influencing adherence to ART 
with particular focus on patients’ knowledge about ART and HIV/AIDS, stigma and 
discrimination, alcohol use and depression. Additionally, components of the data collection 
tool and how to explain the survey questions to the participants were discussed. The two 
data collectors divided the number of participants in to 178 and 177 and gathered the 
information in alternating fashion. The researcher controlled the data collection process 
through providing supportive supervision. The data collection process took two months to 
complete.  
 
3.4.1 The research instrument   
 
Structured interviews were used for data collection. A structured interview is an oral 
communication between the data collector and the subject, in order to obtain information 
for the researcher. A structured interview is a flexible technique that allows researchers to 
ask questions in a way that is understood by the respondents. Response rates to 
structured interviews are higher than self-completion questionnaires. Besides, it allows 
getting information from those respondents who are unable to complete questionnaires 
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because of blindness, or their inability to read and write. The disadvantages of this 
technique include longer time to collect data and more costs compared to using postal 
questionnaires (Burns & Grove 2005: 396-397). The purpose of the structured interviews 
was to ask respondents about their ART adherence and to determine which patient-
related-factors affected ART adherence.  
 
A structured interview schedule was developed to collect data from patients. The interview 
schedule is a data collection document for collecting specific information from respondents 
(Fathalla 2004:57). Before the interview schedule was initially used as a data collection 
instrument, it was pre-tested. During the pre-testing phase ambiguous words and 
sentences were identified by the data collectors. The respondents were also asked at the 
end of the interview how they felt about the nature, style and timing of the questions. All 
identified problems were addressed during the revision of the data collection instrument. 
Individual questions were structured to avoid ambiguities; interviewers were trained to ask 
questions in a uniform way. The language of interview was Amharic as this is the national 
language of Ethiopia and well understood by the patients. The originally developed 
interview schedule in English was translated in to Amharic with a licensed translator. The 
data collectors are well versed both in English and Amharic communication. They were 
recruited based on their college level education and prior experience of data collection. 
Hence, the data collectors accurately documented the respondents’ Amharic responses in 
English. The interview schedule was divided in to the following six components.  
 
Section A: General and demographic questions, including background information of the 
respondents, were asked in this introductory section. Aspects covered included the ART 
patients’ unique codes, ages, gender, residence types, levels of education and marital 
status. 
 
Section B: The questions in this section pertained to the duration of time since the each 
patient’s HIV positive status had become known to him/her, and to the patient’s adherence 
levels on his/her ART regimen. The adherence level is obtained by dividing medication 
doses taken by medication doses prescribed. 
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Section C: This section covered questions about the patient’s knowledge about HIV and 
ART, using seven questions. The questions focused on patients’ knowledge of HIV 
transmission, HIV prevention knowledge and HIV in-depth knowledge which included ART. 
 
Section D: These questions addressed stigma and discrimination experienced by the ART 
patient, focusing on the ART patients and their perceptions of their feelings of stigma and 
discriminatory actions experienced by them. 
 
Section E: This section’s questions pertained to symptoms of depression. The questions 
were asked in such a way that patients could respond to each question as either ‘yes’ or 
‘no’. The total number of ‘yes’ responses were added to reach a potential diagnosis of 
depression. Depression was diagnosed if five or more of the following symptoms occurred 
nearly every day for two weeks with at least one of the symptoms being depressed mood 
or loss of interest or pleasure (Reus 2005:2553):  
• Depressed mood most of the time  
• A dramatic change in appetite resulting in a 5% change in weight (gain or loss),  
• Over sleeping or sleep disturbance 
• Inability to concentrate, think clearly or make decisions 
• Agitation, restlessness, and irritability 
• Diminished interest or inactivity and withdrawal from pleasurable activities 
• Fatigue or loss of energy nearly everyday 
• Feelings of worthlessness and helplessness and  
• Thoughts of death or suicide.    
 
Section F: The section asked questions about alcohol use, to gather data on the type, 
frequency and amount of alcohol consumed by each ART patient. Munne (2005:36) 
classified the frequency of alcohol drinking in the past 12 months and the amount of 
drinking as five or more drinks, by using the following typology: 
• Current abstainer: never had a drink or had none in the past year 
• Infrequent light drinker: drinking less often than weekly, always less than five drinks 
per one occasion 
• Frequent light drinker: drinking weekly and less than five drinks per occasion 
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• Infrequent heavy drinker: drinking less than weekly, sometimes more than five 
drinks per occasion. 
• Frequent heavy drinker: drinking weekly and more than five drinks per occasion 
 
There were also open ended questions in the above mentioned sections that enabled ART 
patients to explain their personal experiences about factors influencing their ART 
adherence levels. These were questions about patients’ knowledge about ART and 
HIV/AIDS and stigma and discrimination. 
 
3.4.2 Data collection procedures  
 
The structured interviews were conducted in the pharmacy since this was the last place 
the patients visited before leaving the ART clinic. Nine patients were interviewed per day 
over for a period of two months. The two data collectors alternated doing patient 
interviews. On average it took 25 minutes to interview a single respondent. The researcher 
controlled the data accuracy by observing whether the data collectors recorded the exact 
information. 
  
3.4.3 Data management and analysis 
 
The completed hard copy interview schedules were kept locked up the researcher. No 
patient’s name was written on the interview schedule.  Although each patient’s file number 
had been recorded, only the researcher could trace any specific file should it be necessary 
to check any recorded information.   
 
Different statistics and measures of association were applied to test a null hypothesis at P-
value of <0.05. 95.0% confidence levels were used to calculate a range of likely values for 
the difference in mean outcome (adherence level) of the population. Since the sample size 
was larger than 60, z-tests were used to calculate p-values (Sterne & Kirkwood 2003: 60-
61). There were also exposure variables with more than two categories and hence 
analysis of variance (ANOVA) was employed; specifically in comparison of adherence 
levels between different expectations of the patients. Odds ratios (ORs) were considered, 
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since this was a cross-sectional analytic study. The alternative hypothesis stated that a 
relationship exists between patient-related factors influencing adherence levels. The 
dependant variable was adherence level while the independent variables were patients’ 
knowledge about HIV and ART, HIV/AIDS stigma and discrimination, depression and 
alcohol use. The data gathered had both categorical and numerical figures. Measures of 
association (odds ratio) across the different independent variables were used to assess 
the association between those who adhered to ART and those who did not.  
 
Simple linear regressions and multiple linear regression analyses were used to examine 
the dependency of adherence level on one and on several different exposure variables. 
Since different variables were considered, multivariate analysis was used to examine 
these associations. Correlation coefficients were used to determine whether the 
relationships between these independent and dependant variables were positive. The type 
and number of factors associated with either of the two levels of adherence were analysed. 
The percentage of adherence was calculated for each drug by dividing the number of pills 
taken by the number of pills prescribed. For these statistical analysis procedures the 
Statistical Package for the Social Sciences (SPSS version 17.0) computer software was 
used.  The services of a statistician were employed to do the actual statistical calculations 
and to assist with the interpretations of the statistical results.   
 
3.4.4 Reliability  
 
The precision of a study indicates consistent results in its measurement or finding and 
whether the same result would be found, if the measurements were taken or the study was 
conducted repeatedly. Precision is also called reliability. Factors that influence precision of 
study results including random sampling error and random measurement error (Abdool 
Karim & Myer 2007). Reliability is used to indicate the consistency of a particular 
instrument in measuring the concept of interest (Burns & Grove 2005:374-375). That 
means if different data collectors are used to measure a particular concept, the data 
should be comparable. Reliability testing is also considered to be a measure of the amount 
of random error in the measurement technique. It is concerned with characteristics such as 
dependability, consistency, precision, and comparability.  A reasonable sample size was 
calculated assuming 95.0% confidence interval, 50.0% frequency of adherence and 5.0% 
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worst acceptable result (Sayed 2007:347). During the pre-test phase of the data collection 
instrument, the interviewer identified and recorded words and sentences that were not 
understood and questions that required prompting or further explanations. The interviewer 
also recorded the time taken to complete each interview. At the end of each pre-test 
interview, the respondent was asked how he or she felt about the nature, style and timing 
of the questions. Finally, all the observed shortcomings were addressed during the revision 
of the data collection instrument. 
 
3.4.5 Validity 
 
According to Ulin, Robinson and Tolley (2005:25) validity is the extent to which a 
measurement could be trusted. Validity can also be mentioned as the closeness of a 
measurement towards a true finding. Factors that influence validity of study results include 
selection bias, information bias and the presence of confounding variables (Abdool Karim 
& Myer 2007). The best method of preventing selection bias is to ensure that the 
participants sampled are representative of the target population of interest. This study 
ensured that the sample was a random selection of the target population because the 
inclusion and exclusion criteria were used to identify the population from which a random 
sample had been selected. Information bias in this study was prevented by ensuring that 
variables were measured (by how questions were asked and variable defined) in the same 
way for all participants. 
 
3.4.5.1 Content validity 
 
According to Burns and Grove (2005: 377-378) content validity examines the extent to 
which the instrument measures the major elements that needed to be considered. For this 
particular study, content-related validity was achieved through two steps. An extensive 
literature search was done to ensure that the data collection instrument had all the 
necessary questions for addressing ART-related adherence issues. The second step was 
consultation with experts who were working as ART trainer, HIV/AIDS programme 
manager, statistician with experience in data collection tool development, health 
researcher and research advisor. A total of three experts from health background and one 
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expert from statistics consulted for this purpose. Their comments were included to ensre 
that the instrument addressed all the major elements. 
 
3.4.5.2 Construct validity 
 
Construct validity occurs when the theoretical constructs of cause and effect accurately 
reflect the real world model. It ensures that the data collection instrument measures what it 
intends to measure (Types of validity 2010). For this study all exposure and outcome 
variables were carefully written in the instrument so that the questions were clearly 
understood by the respondent and data collectors. Besides, the data collectors were 
adequately trained to collect all the needed information. The relationship between patient-
related factors and adherence to ART were in agreement with other studies. This indicated 
that  construct validity of the instrument had been achieved. 
 
3.4.5.3 Face validity 
 
Face validity is a measure of how representative the measure is at face value. It is a more 
general measure and often potential respondent have input (Face validity 2010). During 
the pre-test phase of this study, respondents were asked about their opinions of the 
instrument. The questions were clearly structured and the responses were easily recorded 
by the data collectors. 
 
3.5 MEASUREMENT 
 
The measurement used for adherence to ART was based on patients’ self reported 
answers in response to specific questions. The literature review indicates that self-reports 
could be used to measure adherence levels (Murri et al 2000:123-128; Sullivan et al 
2007:3; Mannheimer et al 2008:165). Questions enquired about patients’ duration on ART, 
specific ARV regimens, three day and seven day recalls of ART adherence and reasons 
for missing ARV doses. The adherence level was calculated by dividing ARVs taken by 
prescribed drugs. Even though questions were asked about the recall periods at three and 
seven days, adherence level calculations were done for the seven day recall periods only. 
The cutoff point for considering someone adherent was at the 95.0% level (those who 
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adhered ≥95.0% were considered to be optimally adherent while those who adhered 
<95.0% were regarded as being sub optimal ART adherent).  
 
3.6    ETHICAL CONSIDERATIONS  
 
The proposal was submitted to the Research and Ethics Committee of the Department of 
Health Studies, Unisa and to the participating hospital’s institutional review board  (IRB) 
clearance. This was done to confirm that the rights and welfare of the individuals involved 
were protected, the appropriate methods were used to secure informed consent and the 
potential benefits of the investigation were greater than the risks.  Informed consent must 
ensure that participant understands the following things: possible risks and benefits, 
voluntary participation, assurance of confidentiality, the purpose of the research, how 
he/she was chosen to participate, data collection procedures and whom to contact with 
questions and concerns (Ulin et al 2005:58). The different human rights that required 
protection in research are; the right to self determination, the right to privacy, the right to 
anonymity and confidentiality, the right to fair treatment and the right to protection from 
discomfort and harm (Burns & Grove 2005:181). The information sheets and the interview 
schedules were available in both English and Amharic.   
 
The right to self determination was protected through treating subjects as autonomous 
agents by informing them about the proposed study and allowing them to voluntarily 
choose to participate or not.  They were also informed that they had the right to withdraw 
from the study at any time without incurring any penalties. The right to privacy was 
protected by not disclosing the patient’s information to any third party during interviewing; 
this was achieved through finding an appropriate room for each interview. The right to 
anonymity was protected through anonymous collection of information. Respondents were 
not identified by their key identifiers like name, home number, telephone number or postal 
address when the research report was written. Patients’ interview schedule were marked 
consecutively beginning with 001. Even through the patients ART unique numbers were 
recorded, the right to confidentiality was protected by not sharing this private information 
with others.  
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The right to fair treatment was protected through fair selection and treatment of 
respondents by using simple random sampling. The right to protection from discomfort and 
harm was achieved since the study had minimal to no risk for physical, emotional, social or 
economic harm. Informed consent was obtained from every respondent of the study to the 
degree that they were capable, and documented that they had the opportunity to choose 
whether or not to participate in this research. In other words, informed consent was 
obtained after the objectives of the study and the right to participate or not to participate 
was explained to each respondent. Benefits and risks were balanced as the research 
respondents would benefit when the findings would be shared with the decision makers 
and interventions might be designed and implemented based on such information.  
 
3.7    LIMITATIONS 
REVIEW AND DECIDE TO MOVE TO CHAPTER 5 
• The sample was selected from only one hospital from a total of 9 public hospitals 
and 17 private hospitals providing ART services in Addis Ababa. This makes it 
unrepresentative of the whole population of ART patients in Ethiopia and Addis 
Ababa. Hence, the findings are only generalisable to the participating hospital.  
• The 355 sample respondents were selected using simple random sampling 
technique. As a result both the exposures and outcome variables were collected 
simultaneously. This  limits establishing temporal relationship between the two 
variables and assessing causal associations.  
• Because the participating hospital provided free ARV services, the ART patients 
might have been of lower socio-economic status. Those patients from higher 
economic status might receive their care from private hospitals. Therefore the 
sampled patients might be different from the general ART patients in Addis Ababa. 
• Only structured interviews were used to collect data from patients.   
• No family members and no health care workers were interviewed. 
• In-depth qualitative interviews with the ART patients might have provided  
information about these patients’ lived experiences of being HIV positive and about 
the challenges faced to remain ART adherent. 
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3.8   SUMMARY  
 
The data collection was done on patients at Alert Hospital who have taken ART for at least 
12 months of period. A quantitative, descriptive, cross-sectional and analytical study was 
used to collect data using self report adherence measurement and structured interviews. 
The data were collected from 355 ART patients by conducting structured interviews 
designed for this specific purpose. The data were analysed using the statistical package 
for the social science (SPSS version 17.0).  
 
Chapter 4 presents the analysis and discussion of the data obtained by conducting 
structured interviews with 355 ART patients. 
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CHAPTER 4 
ANALYSIS AND DISCUSSION OF RESEARCH 
RESULTS 
 
4.1 INTRODUCTION  
Chapter 4 presents and discusses the results of this study. The overall purpose of the 
study was to identify personal factors influencing patients’ ART adherence in Addis 
Ababa, Ethiopia. The study’s findings will be used to address those personal factors that 
could present barriers to effective ART adherence. 
The specific objectives of this study were to: 
• Determine the adherence status of ART patients in Addis Ababa, Ethiopia. 
• Identify the influence of patients’ knowledge of HIV and ART on adherence to 
ART in Addis Ababa, Ethiopia. 
• Assess the influence of HIV stigma and discrimination on adherence to ART in 
Addis Ababa, Ethiopia. 
• Evaluate the influence of depression on adherence to ART in Addis Ababa, 
Ethiopia. 
• Identify the influence of alcohol use on adherence to ART in Addis Ababa, 
Ethiopia. 
 
4.2 PATIENTS’ LEVELS OF ART ADHERENCE 
 
At least 95% ART adherence is required to suppress viral replication, show clinical 
improvement and increase the CD4 count (WHO 2006:70). If this adherence level is not 
maintained then it has public health implications and poor personal health outcomes 
(WHO 2003:95). Adherence was calculated using ART patients’ self reports in this study 
for the preceding seven days. The actual figure was obtained by dividing the total 
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number of pills reportedly ingested by the total number of pills prescribed for the 
preceding seven days.  
 
Out of the 355 patients, 94 (26.5%) were non-adherent, with less than 95% adherence 
level, and 261 (73.5%) of them were adherent at a 95-100% adherence level. There 
were 6 (1.7%) patients with 0-5% adherence level. The adherence levels ranged from 
0% to 100%; the lowest, 0% indicated that the patient did not take any pills during the 
preceding seven days and the highest 100% indicated that the patient took all pills 
prescribed for the past seven days.  
 
Table 4.1 Adherence levels (n=355) 
 
Adherence level Frequency Percent Cumulative percent 
0-5% 6 1.7 1.7 
55-59% 5 1.4 3.1 
60-64% 1 0.3 3.4 
65-69% 1 0.3 3.7 
70-74% 3 0.8 4.5 
75-79% 2 0.6 5.1 
80-84% 14 3.9 9.0 
85-89% 35 9.9 18.9 
90-94% 27 7.6 26.5 
95-100% 261 73.5 100.0 
Total 355 100.0  
 
More than two thirds (73.5%; n=261) of the respondents took their ARVs as prescribed.  
This study supports the findings of other studies that patients in resource-poor countries 
can adhere to their ARVs as prescribed (Mugusi et al 2009:1231; Carlucci et al 
2008:618). 
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Figure 4.1 Adherence/non adherence percentages among ART patients (n=355) 
 
4.3 DEMOGRAPHIC DATA 
 
This section presents demographic data, followed by clinical data with discussions 
about the adherence levels in association with personal factors. All figures are rounded 
off to the first decimal place. The demographic section addresses the results pertaining 
to the participants’ gender, ages, educational levels and marital status. 
 
A total of 355 (100%) ART patients, 130 (36.6%) males and 225 (63.4%) females, who 
were PLHIV ≥18 years of age and who had started ART at least twelve months 
previously were selected for the study using simple random sampling. Those patients 
excluded by study criteria upon sampling were substituted with other patients to attain 
the required power. Table 4.2 shows the key characteristics of the respondents. 
 
 
 
 
 
 
73.5% (n=261) 
26.5% (n=94) 
Adherent 
Non-adherent 
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Table 4.2 Characteristics and profile of respondents (n=355) 
 
Variables  Values 
Age range (years) 20-67 
Mean age (years) 36.43 
Female (number) 225 
Male(number) 130 
Baseline CD4 cell count range (cells/mm3) 4-478 
Most recent CD4 cell count range (cells/mm3) 17-1053 
 
 
 4.3.1 Gender  
 
Although in Ethiopia the overall percentage of males (50.5%) and females (49.5%) are 
almost equal, the proportion differs between urban and rural areas. In urban areas the 
male to female proportion is 49.7% to 50.3% and in rural areas 50.6% to 49.4% 
respectively. In urban areas females are more in number but in rural areas the reverse 
is true. In Addis Ababa the total percentage of males is (47.6%) and females (52.4%) 
(FDRE/PCC 2008:7-14).  
 
 
Figure 4.2 Proportion by gender of sampled patients on ART (n=355) 
 
36.6% (n=130) 
63.4% (n=225) 
Male 
Female 
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In this study there were more females 63.4 % (n=225) than males 36.6% (n=130) which 
reflects the higher HIV prevalence among females normally seen in the urban areas of 
Ethiopia. The adult HIV prevalence rate in urban areas is higher among females, 9.25% 
compared to males (6.2%) (EFMOH/HAPCO 2007a:07). 
 
Out of the 94 non adherent respondents, 43.6% (n=41) were males and 56.4% (n=53) 
were females (see figure 4.3). Among the 261 adherent patients, 34.1% (n=89) were 
males. The adherence level of males was significantly different from that of females (p= 
0.05, 95%CI= -6.40,-0.01). This result could indicate that females were more ART 
adherent than males.  This difference could possibly be explained by the fact that more 
males than females were employed outside their homes, working as drivers and/or 
farmers, and might be less unlikely to take their medications with them to their 
workplaces.  
 
 
Figure 4.3 Relationship between ART adherence and gender (n=355)  
 
This finding is supported by a South African study showing that women were more 
adherent than men based on self reported adherence rates validated by virological 
suppression, CD4 counts and clinical outcomes (Boulle, Michaels & Hildebrand 2004). 
There is also a contradictory study from Nigeria, showing that females were less 
adherent. According to Uzochukwu et al (2009:192) females in Nigeria who were single 
89 
172 
41 
53 
0 
20 
40 
60 
80 
100 
120 
140 
160 
180 
200 
Male Female 
Co
un
t 
Adherent 
Non-adherence 
51 
 
and had higher educational status, had significantly higher levels of ART non-
adherence. 
 
Table 4.3 Gender versus adherence (n=355) 
 
 Adherence  
Non 
adherent 
(<95%) 
Adherent  
(95-100%) 
Total 
Gender Male Count 41 89 130 
  % within gender (males) 31.5% 68.5% 100.0 
  % of total 11.5% 25.1% 36.6% 
 Female Count 53 172 225 
  % within gender 
(females) 
23.6% 76.4% 100.0 
  % of Total 14.9% 48.5% 63.4% 
Total  Count 94 261 355 
  % within gender 26.5% 73.5% 100.0 
 
4.3.2 Age 
 
The patients’ ages ranged from 20 to 67 with an average of 36.4. The age 30-34 year 
group constituted the largest group of patients (n=77), followed by the age 35-39 year 
group (n=72).  Accordingly the most adherent patients were identified in the age group 
30-34 years (n=55), followed by those aged 35-39 (n=53). In the age group 25-29 there 
were 47 adherent respondents.   
Age was not significantly associated with adherence (p=0.15), as shown in table 4.4. 
This result is similarly reported from a study done in Nigeria showing no significant 
association between age with ART adherence levels (Afolabi, Ijadunola, Fatusi & 
Olasode 2009:9). According to Uzochukwu et al (2009:192) being female, over 35 years 
old and having higher educational status were significantly associated with non-
adherence, contrary to this study’s findings. 
 
 
52 
 
Table 4.4 Relationship between adherence and age (n=355) 
Age Count Non-adherent 
(<95%) 
Adherent (95-
100%) 
TOTAL 
18-24 Count 6 14 20 
% within adherence 6.5% 5.3% 5.6% 
25-29 Count 21 47 68 
% within adherence 22.3% 18.0% 19.2% 
30-34 Count 22 55 77 
% within adherence 23.4% 21.1% 21.7% 
35-39 Count 19 53 72 
% within adherence 20.2% 10.3% 20.3% 
40-44 Count 12 27 39 
% within adherence 12.8% 10.3% 11.0% 
45-49 Count 4 40 44 
% within adherence 4.3% 15.3% 12.4% 
50-54 Count 7 13 20 
% within adherence 7.4% 5.0% 5.6% 
55-59 Count 3 3 6 
 % within adherence 3.2% 1.1% 1.7% 
60-64 Count 0 6 6 
 % within adherence .0% 2.3% 1.7% 
65-69 Count 0 3 3 
 % within adherence .0% 1.1% .8% 
 Count 94 261 355 
% within adherence 100.0% 100.0% 100.0% 
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Figure 4.4 Relationship between adherence and age (n=355) 
 
4.3.3 Education levels 
 
Out of 355 respondents, 38 (10.7%) had never been to school, 133 (37.5%) had 
attended primary school, 52 (14.6%) secondary school, 104 (29.3%) high school and 28 
(7.9%) higher education institutions. Out of the 261 adherent patients, 103 (39.5%) 
attended primary education, 73 (28.0%) school, 40 (15.3%) secondary school and 26 
(10.0%) had never been to school. There was no association between education level 
and adherence status (p=0.638, two tailed tests). Higher levels of education were not 
associated with higher levels of ART adherence.  
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Table 4.5   Level of education attained versus ART adherence (n=355) 
 
Highest level of 
education 
 Non-Adherent 
(Less than 
95%) 
Adherent 
(95-100%) 
TOTAL 
Not been to school Count 12 26 38 
% within highest 
level of education 
passed  
31.6% 68.4% 100.0% 
Grade 1-6 
(Primary) 
Count 30 103 133 
% within highest 
level of education 
passed 
22.6% 77.4% 100.0% 
Grade 7-8 
(Secondary) 
Count 12 40 52 
% within highest 
level of education 
passed 
23.1% 76.9% 100.0% 
Grade 9-12 
(High school) 
Count 31 73 104 
% within highest 
level of education 
passed 
29.8% 70.2% 100.0% 
University/college 
(Higher institution) 
Count 9 19 28 
% within highest 
level of education 
passed 
32.1% 67.9% 100.0% 
TOTAL Count 95 261 355 
TOTAL % %  within highest 
level of education 
passed 
26.5% 73.5% 100.0% 
 
According to this study there was no evidence that a person’s educational level affected 
his/her ART adherence level. Whether a person had been educated or not, he/she 
could take his/her ARVs as prescribed by the healthcare provider. This finding is 
consistent with another study which indicated that low literacy levels were not 
associated with low levels of ART adherence (Paasche-Orlow et al 2006:838). 
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Figure 4.5 Relationship between adherence and education level (n=355) 
4.3.4 Marital status 
 
Of the 355 patients, 156 (43.9%) were married, 89 (25.1%) widowed, 48 (13.5%) single, 
37 (10.4%) divorced and 25 (7.0%) separated. Among the 261 adherent patients the 
largest number was found among the 115 (44.1%) married respondents, followed by the 
67 (25.7%) who had been widowed. However, there was no association between 
marital status and adherence levels (p=0.30, two tailed test of chi-square). This finding 
related to whether or not a person was married, divorced, single, separated or widowed, 
but it did not indicate whether the person was living alone or with others. A single, 
separated or widowed person could be living with other individuals, and this might have 
impacted on his/her ability to adhere to his/her ART.   
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Table 4.6 Marital status versus adherence (n=355) 
Marital 
status 
Count and % Non-
adherent(<95%) 
Adherent (95-
100%) 
TOTAL 
Single Count 10 38 48 
% within marital 
status 
20.8% 79.2% 100.0% 
% within optimal 
suboptimal 
adherence 
10.6% 14.6% 
 
13.5% 
Married  Count 41 115 156 
% within marital 
status 
26.3% 73.7% 100.0% 
% within optimal 
suboptimal 
adherence 
43.6% 44.1% 43.9% 
Divorced Count 10 27 37 
% within marital 
status 
27.0% 73.0% 100.0% 
% within optimal 
suboptimal 
adherence 
10.6% 10.3% 10.4% 
Separated Count 11 14 25 
% within marital 
status 
44.0% 56.0% 100.0% 
% within optimal 
suboptimal 
adherence 
11.7% 5.4% 7.0% 
Widowed Count 22 67 89 
% within marital 
status 
24.7% 75.3% 100.0% 
% within optimal 
suboptimal 
adherence 
23.4% 27.7% 25.1% 
TOTAL Count 94 261 355 
% within marital 
status 
26.5% 73.5% 100.0% 
 
According to Knodel, Kespichayawattana & Wiwalwanich (2010:6) in a study conducted 
at Thailand, family members could support the patient to take his or her medication on 
time. Smith and Mbakwem’s (2007:38)  study done in Nigeria, found that ART 
programmes need to acknowledge and create enabling environments for marriage and 
reproduction; while addressing disclosure, adherence to ART and prevention issues.  
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Figure 4.6 Relationship between adherence level and marital status (n=355) 
 
4.4 CLINICAL DATA 
 
This section presents the clinical data gathered from participants’ records. 
 
4.4.1 CD4 cell count values 
 
Patients are initiated on ART based on their CD4 cell count and their WHO HIV/AIDS 
clinical stage (WHO 2006:13-16). ART is initiated when the CD4 cell count is 
<200cells/mm3, irrespective of the clinical stage. When the CD4 count is between 200 
cells/mm3 and 350cells/mm3, ART is initiated based on the patient’s WHO stage. The 
severity of the illness increases as the stages progress from 1 to 4 (WHO 2007:12). The 
CD4 cell counts, gathered at baseline and most recently available in the patients’ 
charts, were used for this analysis. The baseline CD4 count ranged from 4 to 478 
cells/mm3 and the most recent CD4 cell count ranged from 17 to 1053 cells/mm3. 
 
Figure 4.7 shows the result of changes in CD4 cell count from the baseline (before 
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weak positive relationship between the baseline CD4 count and the most recent CD4 
count with a Pearson Correlation Coefficient of 0.417, meaning the higher pre-treatment 
cell count, the higher the post treatment cell count. The regression line of the most 
recent CD4 count on the baseline CD4 cell count is y=0.977x+271.565, where y is the 
most recently counted CD4 cell and x is baseline CD4 cell count. The gradient of the 
regression line is 0.977 which means as the baseline CD4 count increase by one then 
the most recent CD4 count rise by 0.977.  
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Scatterplot: CD4 cell count baseline (when ART started) versus most 
recent (currently) 
 
Although the relationship between the two cell counts is weak with a pearson correlation 
coefficient of 0.417, both coefficients of the regression line shows a statistically 
significant association (p=0.01). Thus baseline CD4 cell count plays a significant role in 
determining the most recent CD4 count. The coefficient of determination, r2, is 0.174 
which means that 17.4% of the most recent CD4 counts are determined by the baseline 
CD4 cell counts 
 
 
 
 
 
 
 
 
59 
 
Table 4.7 Statistics: CD4 cell count at baseline versus CD4 cell count most 
recently 
 
Model 
Unstandardised 
Coefficients 
Standardised 
Coefficients 
t Sig. B Std. Error Beta 
(Constant) 271.565 18.515  14.668 .000 
CD4 count in cell/mm3 
when ART started 
.977 .113 .417 8.616 .000 
 
4.4.2 WHO HIV/AIDS stage 
 
WHO classifies HIV/AIDS infection into four stages and this is used in deciding ART 
initiation. The stages are stage I (asymptomatic), stage II (mild symptoms), stage III 
(advanced symptoms) and stage IV (severe symptoms) (WHO 2007:12). Out of 355 
respondents, 179 were classified as being in WHO’s HIV/AIDS stage I; 83 (23.4%) in 
WHO’s stage II; 57 (16.1%) in stage III and 14 (3.9%) in stage IV. The rest, 22 (6.2), did 
not have any WHO staging reported in their records. A higher number of patients who 
were ART-adherent were found in WHO stage I (n=141; 57.8%) followed by WHO stage 
II (n=56; 23.0%). There was a significant association between WHO HIV/AIDS staging 
and adherence (p=0.039). The proportion of patients who adhered to treatment 
increased as the WHO clinical stage decreased, indicating that when patients adhered 
to ART, the associated severity of their illness could be reduced.  
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Figure 4.8 Relationship between adherence and WHO HIV/AIDS stage (n=333) 
 
4.5 CORRELATION BETWEEN ADHERENCE AND PATIENTS’ KNOWLEDGE 
LEVELS 
 
Patients’ knowledge levels were assessed using questions pertaining to HIV/AIDS and 
ART. Nine questions were asked and the knowledge was scored out of 100%. The 
questions focused on the mode of transmission of HIV, difference between HIV and 
AIDS, benefits and adherence to ART. The mean knowledge score was 61.84% (range 
18.89% to 86.66%; standard deviation of 10.92). Figure 4.9 does not show a linear 
relationship between adherence and knowledge score. Spearman’s Correlation 
Coefficient is -0.002, suggesting no association. Hence, there no association was found 
between adherence level and knowledge score. Additionally, at the 5% significance 
level, the results indicated no statistically significant association (p=0.967).  People with 
higher knowledge score (good knowledge of HIV and ART), were reportedly not more 
likely to be adherent to ART compared to those with poorer knowledge levels, as 
measured in this study. 
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Table 4.8 Knowledge score versus adherence level (n=355) 
 
 Adherence  
Non-adherent 
(<95%) 
Adherent  
(95-100%) 
Total 
Grouped 
knowledge 
Score 
18-24% Frequency 1 0 1 
25-29% Frequency 0 1 1 
30-34% Frequency 1 2 3 
35-39% Frequency 3 4 7 
40-44% Frequency 2 10 12 
45-49% Frequency 8 12 20 
50-54% Frequency 13 36 49 
55-59% Frequency 10 29 39 
60-64% Frequency 10 54 64 
65-69% Frequency 18 64 82 
70-74% Frequency 12 22 34 
75-79% Frequency 11 22 33 
80-84% Frequency 3 5 8 
85-89% Frequency 1 0 1 
Total  Frequency 94 261 355 
 % of total 26.5% 73.5% 100% 
 
A Zambian study found that lack of information about HIV and ART among females was 
associated with poor adherence (Murray et al 2009:84). The same finding was 
documented in a South African study with a knowledge score of 86% at Soweto 
(Nachega et al 2005:199). Both studies contrast with the finding of this study indicating 
no association between knowledge and ART adherence level.  
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Figure 4.9 Scatterplot: Relationship between adherence and knowledge score 
 
 
4.6 ADHERENCE, STIGMA AND DISCRIMINATION 
 
Stigma and discrimination were divided into internalised stigma, perceived stigma and 
experienced discrimination to facilitate the analysis of this research. Each stigma type 
was presented in association with adherence in this section. 
 
4.6.1 Relationship between adherence and internalised stigma 
 
Stigma is a negative attitude towards a group of people due to their unique attributes 
(such as HIV status) (Luna-Cadena et al 2004:01). The authors further discussed that a 
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patient develops internalised stigma when he/she treats himself differently or develops 
stigmatizing feelings due to fear of reactions by other people based on his/her specific 
attribute(s). This stigma is related to shame, fear and guilt, and can lead to isolation, 
deception, and camouflage. 
 
In this study internalised stigma was identified based on the patients’ responses to three 
internal stigma questions. Out of the 355 patients, 161 (45.4%) had reportedly 
developed internalised stigma while 194 (54.6%) did not. Out of the 261 adherent 
patients, 161 (61.7%) did not develop self stigma. Out of the 94 non-adherent 
respondents, 61 (64.9%) developed internalised stigma. Adherence level ranged from 
0-100% for both internalised stigma and non-internalised stigma patients. However, out 
of the 8 patients with adherence levels of 0-5%, 4 (50.0%) had experienced internalised 
stigma and 2 (25.0%) patients had not experienced internalised stigma.  
 
 
 
Figure 4.10 Internalised stigma status (n=355) 
 
At a 5% significance level, the z-test statistic showed a significant association between 
internalised stigma and adherence (p=0.003; 95%CI= -7.70,-1.55). Further adherence 
levels were grouped into adherent and non-adherent categories and the strength of 
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association with internalised stigma was calculated from odds ratio (OR) of 2.89 and 
95% CI of 1.77, 4.74. This indicated that people with internalised stigma were less likely 
to take ARVs as prescribed. This finding is consistent with other results. According to a 
study in the USA, internal stigma and other factors such as denial, life stress and 
adverse ARVs’ side-effects were barriers to ART adherence (Konke-Parker et al 
2008:98). Another study found that people with internalised stigma were three times as 
likely to report suboptimal adherence to HIV medications (Sayles et al 2009:1103). 
 
Table 4.9 Logistic regression: internalised stigma versus adherence  
 
  
B S.E. Wald df Sig. Exp(B) 
95% C.I. for 
EXP(B) 
  Lower Upper 
Step 1a StigmaInternal 1.064 .251 17.951 1 .000 2.898 1.772 4.742 
Constant -.543 .378 2.068 1 .150 .581   
 
 
 
 
 
Figure 4.11 Adherence level versus internal stigma (n=355) 
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4.6.2 Relationship between adherence and perceived stigma 
 
Perceived stigma is due to another person thinking negatively about an individual 
because of something s/he develops, such as HIV (OVC support: 2011).  In this study, 
perceived stigma was identified based on the patients’ response to three perceived 
stigma questions. From the 355 respondents, 60 (16.9%) developed perceived stigma 
and 295 (83.1%) did not. Among the 94 non-adherent patients, 34 (36.2%) had 
perceived stigma and of the 261 adherent patients, 235 (90.0%) did not have perceived 
stigma. Adherence levels ranged from 0-100% for both groups who developed 
perceived stigma or did not develop perceived stigma. However, of 6 patients with an 
adherence level of 0-5%, 2 (33.3%) developed perceived stigma and 4 (66.7%) did not 
do so. 
 
Table 4.10 Adherence vs. perceived stigma (n=355) 
 
 Adherence 
Total 
Non-adherent 
(<95%) 
Adherent 
(95-100%) 
Perceived 
Stigma 
Perceived 
stigma 
Count 34 26 60 
% within perceived stigma 56.7% 43.3% 100.0% 
% within optimal or 
suboptimal adherence 
36.2% 10.0% 16.9% 
No 
perceived 
stigma 
Count 60 235 295 
% within perceived stigma 20.3% 79.7% 100.0% 
% within optimal or 
suboptimal adherence 
63.8% 90.0% 83.1% 
Total Count 94 261 355 
% within perceived stigma 26.5% 73.5% 100.0% 
% within optimal or 
suboptimal adherence 
100.0% 100.0% 100.0% 
 
The z-test shows a statistically significant association at a 5% significance level 
between perceived stigma and adherence (p=0.01; 95%CI=-11.66,-3.54). This finding 
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supports that adherence tends to be lower with people having perceived stigma. 
Perceived stigma is associated with patients not taking their pills, possibly because of 
fears of social rejection. This finding is congruent with a study done in five other African 
countries (Lesotho, Malawi, South Africa, Swaziland and Tanzania) which found that 
perceived stigma interfered with adherence to ART and correlated with missed doses of 
HIV/ADS medications (Dlamini et al 2009:384). 
 
 
 
 
Figure 4.12 Adherence level versus perceived stigma (n=355) 
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with an adherence level of 0-5%, 3 (50.0%) had faced discrimination and 3 (50.0%) did 
not face discrimination. Out of the 261 patients with an adherence level of 95-100%, 38 
(14.6%) faced discrimination and 223 (85.4%) did not face discrimination.  
 
Table 4.11 Statistics: discrimination versus adherence (n=355) 
 
 Z-test 
 95% confidence interval 
of the difference 
Z Df Sig. (2-tailed) Lower Upper 
Equal variances 
assumed 
-2.727 353 0.007 -9.638 -1.561 
Equal variances 
not assumed 
-1.906 69.225 0.061 -11.459 0.259 
 
The z-test shows there is a statistically significant association between discrimination 
and adherence at the 5% significance level (p=0.007; 95%CI= -9.6,-1.6). Patients who 
experienced discrimination had lower levels of adherence.  This finding is supported by 
another study which indicated that ; because of stigma and discrimination, people living 
with HIV may not take their medications at the correct time or in the correct way, in 
order to hide their positive status from others (DFID 2007:02). 
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Figure 4.13 Adherence versus discrimination (n=355) 
 
4.7 ADHERENCE AND DEPRESSION 
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Table 4.12 Statistics: depression versus adherence (n=355) 
 
 Z-test 
 95% confidence interval 
of the difference 
Z df Sig. (2-tailed) Lower Upper 
Equal variances 
assumed 
-2.001 353 0.046 -13.809 -0.120 
Equal variances 
not assumed 
-2.823 11.683 0.10 -12.071 -1.857 
 
 
There was a statistically significant association between adherence and depression at 
the 5% significant level (p=0.046; 95%CI=-13.81,-0.12). The strength of the association 
was also determined using an odds ratio (OR=12.40; 95%CI=4.00, 38.46). The odds 
ratio is more than 1 and indicates that depression was a risk factor for adherence to 
ART. 
 
 
 
Figure 4.14 Frequency and percentage of depressed and non-depressed patients 
(n=355) 
 
This finding is supported by other studies. An Ethiopian study (Amberbir et al 2008:5) 
reported that non-depressed patients adhered to ART twice more than depressed 
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patients. Depressed patients had poor moods, even if good things were happening to 
them. As a result depressed patients were not motivated to take their pills as agreed to 
with their health care providers. The same result was also identified in an Indian study 
(Sarna et al 2008:34) that showed depression to be associated with non-adherence to 
ART. This suggests that healthcare providers should identify depression among HIV 
patients as early as possible and manage it to improve ART adherence levels. 
 
 
 
Figure 4.15 The relationship between adherence and depression (n=355) 
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drinker and 3 (3.2%) infrequent heavy drinkers. Adherence levels ranged from 0-100% 
for both current abstainers and infrequent light drinkers; 86-95% for frequent light 
drinkers and 67-95% for infrequent heavy drinkers.  
 
Since the alcohol variable had five categories, one way analysis of variance (ANOVA) 
was used to assess the association between adherence and alcohol. There was a 
statistically significant association between alcohol use and adherence at the 5% 
significance level (p=0.001). This indicated that when the frequency and amount of 
alcohol consumption is high, the probability of ART non-adherence is also high.  
 
Table 4.13 ANOVA: association between alcohol use and ART adherence 
 
 Sum of 
Squares Df 
Mean 
Square F Sig. 
Between 
Groups 
4674.620 3 1558.207 7.483 .000 
Within Groups 73085.309 351 208.220   
Total 77759.929 354    
 
This finding is supported by other studies. Alcohol use is associated with ART non-
adherence even though it cannot be concluded that alcohol consumption was causal in 
nature (Hendershot, Stoner, Pantalone & Simoni 2009:08). In a different study in the 
USA, both moderate and hazardous levels of alcohol use were associated with non-
adherence to ART (Chander et al 2006:414). 
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Figure 4.16 Alcohol consumption versus ART adherence (n=355) 
 
4.9 CONCLUSION  
 
This chapter presented the results of the association between patient ART adherence 
(defined for the last seven days) and demographic, clinical and personal factors. 
Gender was significantly associated with adherence, but there was no association with 
age. Both higher levels of education and knowledge score were not related to higher 
levels of adherence. Marital status alone did not have an effect on increased adherence 
level, however, his study did not investigate the role of other family supports on 
adherence. Baseline CD4 cell count and the most recent CD4 cell counts had a weak 
positive association. WHO HIV/AIDS stage was also associated with adherence to ART 
showing patients with better adherence had less severe illness.  
 
Stigma and discrimination when sub categorised into three types, were all found to be 
associated with adherence. People adhere better to their medication in the absence of 
any type of stigma and discrimination. Alcohol use and a depressed mood were related 
to suboptimal adherence.  
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In summary, the study found that 73.5% of the respondents had optimal adherence and 
26.5% had sub optimal adherence. From the personal factors studied, stigma and 
discrimination, depression and alcohol use were associated with adherence to ART, 
while no association was found with knowledge.   
 
The next chapter will present the conclusions, limitations and recommendations of this 
study and proposed areas for possible future research. 
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CHAPTER 5 
 
CONCLUSIONS, LIMITATIONS AND RECOMMENDATIONS 
 
5.1 INTRODUCTION  
 
The main purpose of the study was to identify the associations between personal 
factors and patients’ adherence to anti-retroviral treatment. Adherence was measured 
by self report among treatment experienced patients (aged 18 and older) at the ALERT 
hospital. The results will be used to make recommendations to address personal 
barriers of adherence to ART. Specifically the conclusions, detailed in chapter 4, were 
used to answer the following research questions:  
• What is anti-retroviral treatment adherence level at one government hospital?  
• What is the association of knowledge, stigma and discrimination, depression and 
alcohol use on adherence to anti-retroviral treatment adherence at ALERT 
hospital? 
 
5.2 OBJECTIVES 
 
The objectives of the study were assessed as to whether or not they had been attained. 
Each objective is listed and then the conclusions are given along with related 
implications and applications. 
 
5.2.1 Determine adherence status of ART patients in Addis Ababa, Ethiopia 
 
Optimal adherence level was set at 95% which is necessary for desired clinical 
outcomes, adequate immunological response and suppressed viral replication. An 
adherence level of 95-100% was found among 73.5% of the respondents at one 
participating hospital. Suboptimal adherence level, less than 95%, was documented 
among 26.5% of patients. This finding aligns with results from other studies of patients 
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in resource limited countries and indicates that patients in these countries are capable 
of adhering as required. 
 
5.2.2 Identify the influence of patients’ knowledge of HIV and ART on adherence 
to ART in Addis Ababa, Ethiopia 
 
In this study, patients had a mean knowledge score of 61.84% when rated on questions 
about HIV/AIDS and ART. There was no correlation between patients’ knowledge and 
adherence to ART with a spearman’s correlation coefficient of -0.002, suggesting that 
patients’ level of HIV/AIDS and ART knowledge was not associated with adherence to 
ART.  
 
Implication: Further study in different health facilities in Ethiopia, if possible 
prospectively over a longer time period, is recommended to investigate the relationship 
between knowledge and adherence to ART. 
 
5.2.3 Assess the influence of HIV stigma and discrimination on adherence to 
ART in Addis Ababa, Ethiopia 
 
Stigma and discrimination were divided into internal stigma, perceived stigma and 
discrimination. The number of respondents with internal stigma was highest (161 out of 
the 355 patients), followed by those experiencing discrimination (n=62) and finally those 
with perceived stigma (n=60). Each of the categories of stigma was associated with 
adherence to ART. People with stigma and discrimination were less likely to adhere to 
their ARVs. 
 
Implication: This finding indicates the necessity to address stigma and discrimination 
by mobilising leaders (religious, secular and government)  to promote and foster respect 
and compassion for people living with HIV/AIDS; empowering people living with 
HIV/AIDS to take the lead in diverse support and advocacy activities; mobilising 
community leaders to encourage openness around sexuality and HIV-related issues 
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within communities by building on positive social norms; raising awareness through 
media, mobilising organisations to implement non-discriminatory policies; ensuring 
redress where cases of discrimination occur and promoting understanding among 
people living with HIV/AIDS of their rights. 
 
5.2.4 Evaluate the influence of depression on ART adherence in Addis Ababa 
 
Depression as mentioned by different studies as well as this research has a negative 
influence on adherence to ART. Among the 19 depressed patients, 78.9% of them were 
found to be non-adherent. The depressed patients showed low levels of adherence and 
did not take their medications as the healthcare providers prescribed.  
 
Implication: Healthcare providers should screen ART patients for depression before 
starting ART. When depressed patients are identified they should get appropriate 
therapy for their depression along with ART adherence counseling. 
 
5.2.5 Identify the influence of alcohol use on adherence to ART in Addis Ababa 
 
The majority of the 355 ART patients were current abstainers from alcohol (n=283; 
79.7%). However, there were 66 infrequent light drinkers, 2 frequent light drinkers and 4 
infrequent heavy drinkers. This study found that greater frequencies and amounts of 
alcohol consumed were associated with lower ART adherence levels.  There was also a 
statistically significant association between alcohol use and adherence to ART at the 
5% significance level.  
 
Implication: Healthcare providers should counsel ART patients about the effects of 
alcohol use on ART adherence and on ART outcomes. Healthcare professionals should 
also teach the general community about the harmful effects of alcohol, including 
informally produced alcohol.  
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5.3 LIMITATIONS OF THE STUDY  
• The sample was selected from only one hospital from a total of 9 public hospitals and 17 
private hospitals providing ART services in Addis Ababa. This makes it unrepresentative 
of the whole population of ART patients in Ethiopia and Addis Ababa. Hence, the 
findings are only generalisable to the participating hospital.  
• The 355 sample respondents were selected using simple random sampling technique. 
As a result both the exposures and outcome variables were collected simultaneously. 
This limits establishing temporal relationship between the two variables and assessing 
causal associations.  
• Because the participating hospital provided free ARV services, the ART patients might 
have been of lower socio-economic status. Those patients from higher economic status 
might receive their care from private hospitals. Therefore the sampled patients might be 
different from the general ART patients in Addis Ababa. 
• Only structured interviews were used to collect data from patients.   
• No family members and no health care workers were interviewed. 
• In-depth qualitative interviews with the ART patients might have provided information 
about these patients’ lived experiences of being HIV positive and about the challenges 
faced to remain ART adherent. 
 
5.4 RECOMMENDATIONS FOR IMPROVING ADHERENCE TO ART IN ETHIOPIA 
 
Adherence level might be improved if the following recommendations were 
implemented. 
• Assessment of adherence level is feasible and can be done by the healthcare 
providers using the patients’ self report. This can be done routinely when the 
patient comes for medication refills. Patients can be supported and counseled to 
take their medications if they have difficulty with adherence. 
• Male adherence supporters can be employed as one strategy to support male 
patients to adhere to their medications given female patients were more adherent 
than male patients.  
• It is important to consider the implementation of facility-based and community 
based programs to alleviate stigma and discrimination. There is a need to timely 
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identify those patients with stigma and discrimination and provide support 
accordingly. It is also important to consider how stigma affects prevention 
strategies in order to improve patients’ adherence to ART adherence. 
• Depression is also a problem that needs to be screened for among all patients 
and treated accordingly, or referred for psychiatric follow up. Depression should 
be emphasised as it presents double problems (the disease itself and its impact 
on adherence to ART). 
• Alcohol use lowers the level of adherence to ART. To improve patients’ health 
condition through better adherence to ART, alcohol use prevention programs 
should be implemented both at the patient, health facility and community levels.  
 
5.5 RECOMMENDATIONS FOR FURTHER STUDIES  
 
Future researchers should investigate the following areas to improve adherence to ART 
in Addis Ababa and other parts of Ethiopia. 
• This study should be duplicated in other health facilities of Addis Ababa and 
Ethiopia since this study was conducted at a single hospital and cannot be 
generalised to the whole of the country.  
• ART adherence levels seen among patients at hospital facilities might not be the 
same as health center adherence levels. The differences between adherence 
levels among hospitals and health centers in Ethiopia should be assessed.  
• As this study was conducted only at a public hospital, it is important to further 
study ART adherence levels at private hospitals and also identify the barriers of 
adherence specific to these facilities. 
• Investigations should be done to identify other factors that are barriers to 
adherence to ART, in addition to those personal factors identified in this 
research. It is also important to consider that barriers of adherence may vary 
among the different regions of Ethiopia.  
• Barriers to adherence among children and adults might not be the same. 
Adherence to ART barriers among children should also be investigated.  
79 
 
• It is also important to investigate the prevalence of depression among ART 
patients. This helps to understand the burden of the problem and propose 
appropriate solutions for its prevention. 
• The rate of hospital admissions among ART patients and this relationship to non-
adherence to ART should be studied. 
• As other outcome measures, the prevalence of opportunistic infections among 
ART patients and their survival and the associated relationship with non-
adherence could be examined.  
 
5.6 CONCLUSION  
 
Among the demographic factors, female gender was associated with greater ART 
adherence levels, whereas age, educational level and marital status did not have any 
association with ART adherence. Baseline CD4 cell counts and the most recent CD4 
cell counts had weak positive associations. WHO HIV/AIDS staging was also 
associated with adherence to ART, indicating that adherent patients experienced less 
severe illnesses. These adherence level findings are similar to those reported by other 
studies in other resource poor countries, confirming that even in resource-limited 
countries patients can maintain high levels of ART adherence. To improve ART 
adherence and subsequent improved health outcomes, it is necessary to design and 
implement practically sound programmes that alleviate the burdens of stigma and 
discrimination, depression and alcohol use among ART patients. 
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Annexure E: Structured interview schedule used for data collection (English version) 
 
Section A:  General questions 
1. Interview ID number in 
the form of 001, 002, 
003… 
 
2. ART unique code  
3. CD4 count (when ART 
started) 
 
4. CD4 count (Currently)  
5. Viral load (when ART 
started) 
 
6. Viral load (currently)  
7. WHO stage when ART 
started 
 
8. WHO stage currently   
9. Interviewer’s name  
10. Date of interview 
DD/MM/YYYY 
 
11. Age in years at last 
birthday 
 
12. Gender Male Female 
 
 
13. What is your religion? Muslim Christian Other 
14. Where do you live Region Sub 
city/woreda 
Kebele (lower level administrative 
unit in Ethiopia) 
 
 
  
15. How far do you live from the hospital? 
16. Can you afford to pay money for transportation to come to this hospital? 
 
 
17. What is the highest 
level of education that 
you passed? 
Not 
educated 
Grade 1-6 Grade 7-8 Grade 9-
12 
Univers
ity/Colle
ge 
18. Marital 
status 
Single Married Divorced Separate
d 
Widowed 
 
 
19. What kind of work do you do? 
 
 
 
20. What is your monthly income in Ethiopian Birr? 
21. With whom do you live? Mark all that apply. 
With Father 
With mother 
With father+mother 
With father+mother+siblings 
With wife 
With husband 
With wife+children 
With husband and children 
With friends 
Other, please specify:  
Section B: Adherence 
1. When were you informed that you are HIV positive?  
Please give date or say how many months ago you 
obtained this knowledge 
 
2. When did you first start taking ART to manage your 
HIV? (Date or number of months) 
 
3. ART regimen (prescribed doses) 
Name of medication Morning 
dose 
Midday 
dose 
Evening 
dose 
Daily total 
# of pills # of pills # of pills # of pills 
1.     
2.     
3.     
     
4. Three-day recall of adherence: Many patients find it difficult to take all their medications 
as prescribed. We would not be surprised if you have missed taking some of your 
medications over the last few days. We are trying to find out how difficult it is for patients to 
take their medication, and what things make it difficult. Please answer these questions as 
honestly as you can about your own experiences. 
Name of medication # of pills 
prescribed 
Yesterday Day before 
yesterday 
3 days ago 
# of pills 
taken 
# of pills 
taken 
# of pills taken 
1.     
2.     
3.     
5. What circumstance led you to miss taking your medication as prescribed? 
Missed dose # 1…………………………………………………………………………. 
Missed dose # 2…………………………………………………………………………. 
Missed dose # 3………………………………………………………………………….. 
6. Some people find it difficult to take their antiretroviral therapy medications on the 
weekends. Thinking about the past seven days, how many times did you miss taking a dose 
of your medication? 
Never 
Once 
Twice 
Three or more times 
 
7. We know that it is difficult to take all your ART just as the Doctor prescribed. Would you 
say that in the past month you: 
Totally followed prescriptions 
Generally followed prescriptions but with some deviations  
Often modified timing and quantities 
Almost never followed prescriptions 
Interrupted treatment 
8. Circumstances and reasons for non adherence in the past month 
In general, what helps you take your medications on time? 
 
 
What circumstances led you to miss taking your pills on time? 
 
 
What other things make it difficult to take all your medications on time? 
 
 
 
9. During the past month, how often did you take a double dose of ART medication after 
missing a dose? 
Never 
Once 
Twice 
More than twice 
10. Did you ever stop taking your ART for 48 hours or longer? 
If yes: how long did you stop taking ART? 
For more than 48 hours and less than a week 
From one to two weeks 
For more than two weeks and less than one month 
For more than one month 
Section C:  HIV/AIDS and ART Knowledge 
1. Please tell me about all the ways in which HIV can be transmitted to persons 
  
 
 
 
2. Please tell me about all the ways which HIV cannot be transmitted to other persons 
 
 
 
 
3. How can people protect themselves from getting HIV? 
 
 
  
 
4. What is the difference between HIV and AIDS? 
 
 
 
5. Can a healthy- looking person have HIV?  Please give a reason for your answer 
  
 
 
 
 
6. Can a healthy-looking person have AIDS? Please give a reason for your answer 
 
 
 
 
 
 
7. Is there a cure for 
AIDS? 
Yes No Do not know 
  
 
8. What are the benefits of the ARV drugs you are taking? 
 
  
9. What could happen if you do not take the ARV drugs as prescribed by your doctor? 
 
 
 
Section D:  Stigma and discrimination 
1. Do you feel guilty because you are HIV+ve?   
2. What do you feel due to your HIV positive?  
a. Angry 
b. despondent 
c. Hopeful for a long happy life 
d. scared of getting very sick 
e. Worthless 
f. Other 
 
 
3. In the past 12 months, have you ever found yourself avoiding or isolating yourself from 
friends or family?  
 
Indicate your opinion about the following judgements of people in your community. 
4. Do some people act as though it is your fault you have HIV?  
 
5. Do people say that you deserve being HIV positive for things you have done?  
 
 
6. Do people seen uncomfortable being around you once they learn you have HIV? 
 
 
Have you faced any of the following in the last 12 months because you were known to 
have, or suspected of having, HIV or AIDS?   
7. Excluded from a social 
gathering (wedding, 
funeral, party, community 
association group) 
 
Yes No 
8. Treated 
differently/shunned at 
social gathering 
Yes No 
9. Abandoned by your 
family/ sent away-to the 
village.  
Yes No 
10. Isolated in household 
for example being made 
to eat alone/ made to use 
separate eating utensils/ 
made to sleep in own 
room. 
 
Yes No 
11. Teased, insulted, or 
sworn at 
Yes No 
 
12. Lost customers who 
bought my 
products/goods or lost a 
job 
Yes No 
13. Lost housing or being 
un able to rent housing 
Yes No 
14. Given poorer quality 
health services for 
example: being passed 
from provider to provider, 
not given medicines, 
denied treatment 
 
Yes No 
15. Had property (land, 
household or other 
goods) taken away 
Yes No 
16. Lost respect/standing 
within the family and/or 
community 
Yes No 
17. Physically assaulted 
(i.e., hit, kicked, punched) 
Yes No 
Section E. Depression 
1. Do you feel depressed 
even when good things 
happen to you. 
 
Yes 
 
If yes for how long and 
please explain in what 
way(s) you feel 
depressed 
 
 
No 
2. Have lost interest or 
pleasure in aspects of 
your life that used to be 
important to you 
 
Yes 
 
If yes for how long 
And please give 
examples 
 
No 
3. Have you lost or 
gained body weight 
 
Yes:  how many 
kilograms did you 
lose/gain 
No 
4. Are you getting a 
sufficient number of 
hours’ restful sleep 
Yes 
 
If yes for how many hours 
do you sleep out of a 24-
No please explain why you regard 
you sleeping as being inadequate 
or too much 
hour day 
 
 
5. Do you do things more 
slowly than before you 
became HIV positive 
 
Yes 
 
If yes for how long have 
you had this experience 
and please give an 
example where your 
activities take longer now 
than previously 
 
 
No 
6. Do you feel tired with 
minimal activity 
 
Yes 
 
If yes for how long have 
you experienced this 
tiredness; please give an 
example of what makes 
you tired easily 
 
 
No 
7. Is it hard for you to 
concentrate on reading or 
thinking 
 
Yes 
 
If yes for how long and 
please give an example 
No 
of such difficulties 
 
 
Section F. Alcohol 
1. During the last 12 
months, how often did 
you drink alcohol?  
 
Never 
 
Monthly or 
less 
2 to 4 
times 
a 
month 
2 to 3 
times a 
week 
4 or more times a 
weeks 
2. What type of alcohol  
you usually drink? 
 
3. What was the size of 
the typical can, bottle, or 
glass of your alcoholic  
drink during the last 12 
months? 
 
1 or 2 3 or 4 5 or 6 7, 8 or 
9 
10 or more 
4. On the days when you 
drank alcohol in the last 
12 months,  how many 
(cans/bottles/glasses) did 
you usually drink in a 
single day?  
 
1 or 2 3 or 4 5 or more 
5. During the last 12 
months, what was the 
largest number of 
(can/bottles/glasses) of 
 
alcohol that you drank in 
a single day? 
 
 
6. How often did you 
drink (number reported in 
previous question) 
(cans/bottles/glasses) 
alcohol in a single day? 
 
 
7. Has a relative or friend 
or a doctor or any health 
worker suggested that 
you reduce your alcohol 
intake? 
 
No Yes, but not in 
the last year 
Yes, during the last year 
 
Thank you very much indeed for answering the questions.  Your answers will contribute 
towards helping the health care workers to supply better ART services in Ethiopia.   You 
have my contact telephone numbers on the card I gave you.  If you have any questions or 
worries, you are welcome to contact me, or your usual health care provider(s). 
 
